A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.
Hypersensitivity reaction (ALLERGIC REACTION) to fungus ASPERGILLUS in an individual with long-standing BRONCHIAL ASTHMA. It is characterized by pulmonary infiltrates, EOSINOPHILIA, elevated serum IMMUNOGLOBULIN E, and skin reactivity to Aspergillus antigen.
A human infant born before 37 weeks of GESTATION.
An infant during the first month after birth.
An infant whose weight at birth is less than 1500 grams (3.3 lbs), regardless of gestational age.
An abnormal increase in the amount of oxygen in the tissues and organs.
'Infant, Premature, Diseases' refers to health conditions or abnormalities that specifically affect babies born before 37 weeks of gestation, often resulting from their immature organ systems and increased vulnerability due to preterm birth.
A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.
An infant whose weight at birth is less than 1000 grams (2.2 lbs), regardless of GESTATIONAL AGE.
The age of the conceptus, beginning from the time of FERTILIZATION. In clinical obstetrics, the gestational age is often estimated as the time from the last day of the last MENSTRUATION which is about 2 weeks before OVULATION and fertilization.
A developmental anomaly in which a mass of nonfunctioning lung tissue lacks normal connection with the tracheobroncheal tree and receives an anomalous blood supply originating from the descending thoracic or abdominal aorta. The mass may be extralobar, i.e., completely separated from normally connected lung, or intralobar, i.e., partly surrounded by normal lung.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
Infections with bacteria of the genus UREAPLASMA.
Any method of artificial breathing that employs mechanical or non-mechanical means to force the air into and out of the lungs. Artificial respiration or ventilation is used in individuals who have stopped breathing or have RESPIRATORY INSUFFICIENCY to increase their intake of oxygen (O2) and excretion of carbon dioxide (CO2).
Hospital units providing continuing surveillance and care to acutely ill newborn infants.
Inhalation of oxygen aimed at restoring toward normal any pathophysiologic alterations of gas exchange in the cardiopulmonary system, as by the use of a respirator, nasal catheter, tent, chamber, or mask. (From Dorland, 27th ed & Stedman, 25th ed)
A disease of bone marked by thinning of the cortex by fibrous tissue containing bony spicules, producing pain, disability, and gradually increasing deformity. Only one bone may be involved (FIBROUS DYSPLASIA, MONOSTOTIC) or several (FIBROUS DYSPLASIA, POLYOSTOTIC).
A human infant born before 28 weeks of GESTATION.
A species of gram-negative bacteria found in the human genitourinary tract (UROGENITAL SYSTEM), oropharynx, and anal canal. Serovars 1, 3, 6, and 14 have been reclassed into a separate species UREAPLASMA parvum.
INFLAMMATION of the placental membranes (CHORION; AMNION) and connected tissues such as fetal BLOOD VESSELS and UMBILICAL CORD. It is often associated with intrauterine ascending infections during PREGNANCY.
Substances and drugs that lower the SURFACE TENSION of the mucoid layer lining the PULMONARY ALVEOLI.
Inhaling liquid or solids, such as stomach contents, into the RESPIRATORY TRACT. When this causes severe lung damage, it is called ASPIRATION PNEUMONIA.
Small polyhedral outpouchings along the walls of the alveolar sacs, alveolar ducts and terminal bronchioles through the walls of which gas exchange between alveolar air and pulmonary capillary blood takes place.
Continuous care and monitoring of newborn infants with life-threatening conditions, in any setting.
A group of hereditary disorders involving tissues and structures derived from the embryonic ectoderm. They are characterized by the presence of abnormalities at birth and involvement of both the epidermis and skin appendages. They are generally nonprogressive and diffuse. Various forms exist, including anhidrotic and hidrotic dysplasias, FOCAL DERMAL HYPOPLASIA, and aplasia cutis congenita.
A genus of the subfamily CERCOPITHECINAE, family CERCOPITHECIDAE, consisting of five named species: PAPIO URSINUS (chacma baboon), PAPIO CYNOCEPHALUS (yellow baboon), PAPIO PAPIO (western baboon), PAPIO ANUBIS (or olive baboon), and PAPIO HAMADRYAS (hamadryas baboon). Members of the Papio genus inhabit open woodland, savannahs, grassland, and rocky hill country. Some authors consider MANDRILLUS a subgenus of Papio.
Refers to animals in the period of time just after birth.
Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.
Developmental bone diseases are a category of skeletal disorders that arise from disturbances in the normal growth and development of bones, including abnormalities in size, shape, structure, or composition, which can lead to various musculoskeletal impairments and deformities.
A genus of gram-negative, nonmotile bacteria which are common parasitic inhabitants of the urogenital tracts of humans, cattle, dogs, and monkeys.
Pathological processes involving any part of the LUNG.
Degeneration of white matter adjacent to the CEREBRAL VENTRICLES following cerebral hypoxia or BRAIN ISCHEMIA in neonates. The condition primarily affects white matter in the perfusion zone between superficial and deep branches of the MIDDLE CEREBRAL ARTERY. Clinical manifestations include VISION DISORDERS; CEREBRAL PALSY; PARAPLEGIA; SEIZURES; and cognitive disorders. (From Adams et al., Principles of Neurology, 6th ed, p1021; Joynt, Clinical Neurology, 1997, Ch4, pp30-1)
An infant having a birth weight of 2500 gm. (5.5 lb.) or less but INFANT, VERY LOW BIRTH WEIGHT is available for infants having a birth weight of 1500 grams (3.3 lb.) or less.
Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)
A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi.
A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)
A species of imperfect fungi from which the antibiotic fumigatin is obtained. Its spores may cause respiratory infection in birds and mammals.
Any suction exerted by the mouth; response of the mammalian infant to draw milk from the breast. Includes sucking on inanimate objects. Not to be used for thumb sucking, which is indexed under fingersucking.
A transient absence of spontaneous respiration.
Articles on conferences sponsored by NIH presenting summary statements representing the majority agreement of physicians, scientists, and other professionals convening for the purpose of reaching a consensus on a subject of interest. This heading is used for NIH consensus conferences as a means of scientific communication. In indexing it is viewed as a type of review article and as a tag for any article appearing in any publication of the NIH Office of Medical Applications of Research (OMAR).
A congenital heart defect characterized by the persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY ARTERY to the descending aorta (AORTA, DESCENDING) allowing unoxygenated blood to bypass the lung and flow to the PLACENTA. Normally, the ductus is closed shortly after birth.
A method, developed by Dr. Virginia Apgar, to evaluate a newborn's adjustment to extrauterine life. Five items - heart rate, respiratory effort, muscle tone, reflex irritability, and color - are evaluated 60 seconds after birth and again five minutes later on a scale from 0-2, 0 being the lowest, 2 being normal. The five numbers are added for the Apgar score. A score of 0-3 represents severe distress, 4-7 indicates moderate distress, and a score of 7-10 predicts an absence of difficulty in adjusting to extrauterine life.
CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).
A respiratory distress syndrome in newborn infants, usually premature infants with insufficient PULMONARY SURFACTANTS. The disease is characterized by the formation of a HYALINE-like membrane lining the terminal respiratory airspaces (PULMONARY ALVEOLI) and subsequent collapse of the lung (PULMONARY ATELECTASIS).
The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
Transducers that are activated by pressure changes, e.g., blood pressure.
The airflow rate measured during the first liter expired after the first 200 ml have been exhausted during a FORCED VITAL CAPACITY determination. Common abbreviations are MEFR, FEF 200-1200, and FEF 0.2-1.2.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
The volume of air remaining in the LUNGS at the end of a normal, quiet expiration. It is the sum of the RESIDUAL VOLUME and the EXPIRATORY RESERVE VOLUME. Common abbreviation is FRC.
Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE.
An anti-inflammatory 9-fluoro-glucocorticoid.
'Bronchial diseases' is a broad term referring to various medical conditions that affect the bronchial tubes, including inflammation, infection, obstruction or narrowing, leading to symptoms such as coughing, wheezing, and difficulty breathing.
An idiopathic, segmental, nonatheromatous disease of the musculature of arterial walls, leading to STENOSIS of small and medium-sized arteries. There is true proliferation of SMOOTH MUSCLE CELLS and fibrous tissue. Fibromuscular dysplasia lesions are smooth stenosis and occur most often in the renal and carotid arteries. They may also occur in other peripheral arteries of the extremity.
Epithelial cells that line the PULMONARY ALVEOLI.
The contents included in all or any segment of the GASTROINTESTINAL TRACT.
Application of positive pressure to the inspiratory phase when the patient has an artificial airway in place and is connected to a ventilator.
A technique of respiratory therapy, in either spontaneously breathing or mechanically ventilated patients, in which airway pressure is maintained above atmospheric pressure throughout the respiratory cycle by pressurization of the ventilatory circuit. (On-Line Medical Dictionary [Internet]. Newcastle upon Tyne(UK): The University Dept. of Medical Oncology: The CancerWEB Project; c1997-2003 [cited 2003 Apr 17]. Available from: http://cancerweb.ncl.ac.uk/omd/)
The removal of secretions, gas or fluid from hollow or tubular organs or cavities by means of a tube and a device that acts on negative pressure.
Abnormalities of motor function that are associated with organic and non-organic cognitive disorders.
The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract.
Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung.
Techniques for effecting the transition of the respiratory-failure patient from mechanical ventilation to spontaneous ventilation, while meeting the criteria that tidal volume be above a given threshold (greater than 5 ml/kg), respiratory frequency be below a given count (less than 30 breaths/min), and oxygen partial pressure be above a given threshold (PaO2 greater than 50mm Hg). Weaning studies focus on finding methods to monitor and predict the outcome of mechanical ventilator weaning as well as finding ventilatory support techniques which will facilitate successful weaning. Present methods include intermittent mandatory ventilation, intermittent positive pressure ventilation, and mandatory minute volume ventilation.
Abnormal development of cartilage and bone.
I'm sorry for any confusion, but "Portugal" is not a medical term and does not have a medical definition. It is a country located in southwestern Europe, known for its rich history, culture, and contributions to various fields including medicine. If you have any questions related to medical topics or definitions, I would be happy to help!
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
FIBROUS DYSPLASIA OF BONE involving only one bone.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Usually high-molecular-weight, straight-chain primary alcohols, but can also range from as few as 4 carbons, derived from natural fats and oils, including lauryl, stearyl, oleyl, and linoleyl alcohols. They are used in pharmaceuticals, cosmetics, detergents, plastics, and lube oils and in textile manufacture. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.
FIBROUS DYSPLASIA OF BONE affecting several bones. When melanotic pigmentation (CAFE-AU-LAIT SPOTS) and multiple endocrine hyperfunction are additionally associated it is referred to as Albright syndrome.
The unborn young of a viviparous mammal, in the postembryonic period, after the major structures have been outlined. In humans, the unborn young from the end of the eighth week after CONCEPTION until BIRTH, as distinguished from the earlier EMBRYO, MAMMALIAN.
Pulmonary diseases caused by fungal infections, usually through hematogenous spread.
An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration.
ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A hereditary disease of the hip joints in dogs. Signs of the disease may be evident any time after 4 weeks of age.
Persistent abnormal dilatation of the bronchi.
Autosomal dominant syndrome in which there is delayed closing of the CRANIAL FONTANELLES; complete or partial absence of the collarbones (CLAVICLES); wide PUBIC SYMPHYSIS; short middle phalanges of the fifth fingers; and dental and vertebral anomalies.
Congenital, often bilateral, retinal abnormality characterized by the arrangement of outer nuclear retinal cells in a palisading or radiating pattern surrounding a central ocular space. This disorder is sometimes hereditary.
Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.
A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Tumors or cancer of the BRONCHI.
Adrenal cortex hormones are steroid hormones produced by the outer portion of the adrenal gland, consisting of glucocorticoids, mineralocorticoids, and androgens, which play crucial roles in various physiological processes such as metabolism regulation, stress response, electrolyte balance, and sexual development and function.
Congenital dislocation of the hip generally includes subluxation of the femoral head, acetabular dysplasia, and complete dislocation of the femoral head from the true acetabulum. This condition occurs in approximately 1 in 1000 live births and is more common in females than in males.

Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. (1/452)

BACKGROUND: The safety and efficacy of inhaled glucocorticoid therapy for asthma stimulated its use in infants to prevent bronchopulmonary dysplasia. We tested the hypothesis that early therapy with inhaled glucocorticoids would decrease the frequency of bronchopulmonary dysplasia in premature infants. METHODS: We conducted a randomized, multicenter trial of inhaled beclomethasone or placebo in 253 infants, 3 to 14 days old, born before 33 weeks of gestation and weighing 1250 g or less at birth, who required ventilation therapy. Beclomethasone was delivered in a decreasing dosage, from 40 to 5 microg per kilogram of body weight per day, for four weeks. The primary outcome measure was bronchopulmonary dysplasia at 28 days of age. Secondary outcomes included bronchopulmonary dysplasia at 36 weeks of postmenstrual age, the need for systemic glucocorticoid therapy, the need for bronchodilator therapy, the duration of respiratory support, and death. RESULTS: One hundred twenty-three infants received beclomethasone, and 130 received placebo. The frequency of bronchopulmonary dysplasia was similar in the two groups: 43 percent in the beclomethasone group and 45 percent in the placebo group at 28 days of age, and 18 percent in the beclomethasone group and 20 percent in the placebo group at 36 weeks of postmenstrual age. At 28 days of age, fewer infants in the beclomethasone group than in the placebo group were receiving systemic glucocorticoid therapy (relative risk, 0.6; 95 percent confidence interval, 0.4 to 1.0) and mechanical ventilation (relative risk, 0.8; 95 percent confidence interval, 0.6 to 1.0). CONCLUSIONS: Early beclomethasone therapy did not prevent bronchopulmonary dysplasia but was associated with lower rates of use of systemic glucocorticoid therapy and mechanical ventilation.  (+info)

Effect of early ambroxol treatment on lung functions in mechanically ventilated preterm newborns who subsequently developed a bronchopulmonary dysplasia (BPD). (2/452)

In a randomized trial in 102 preterm newborns with respiratory distress syndrome (RDS) it has been shown that early Ambroxol treatment (30 mg kg(-1) over the first 5 days) significantly reduces the incidence of RDS-associated complications [bronchopulmonary dysplasia (BPD), intraventricular haemorrhage, post-natal acquired pneumonia]. The aim of the present analysis was to investigate the effect of Ambroxol treatment on lung function in newborns who developed BPD. Respiratory function testing (RFT) was performed immediately after extubation and at day 28. Tidal volume (VT) and respiratory frequency (f) were measured during tidal breathing using the deadspace free flow-through technique. The lung mechanic parameter VT/maxPes was determined by measuring the maximal oesophageal pressure changes, maxPes, with a catheter tip pressure transducer. In the placebo group 36/50 infants were extubated within the first 28 days of life and 13/36 (36%) developed BPD. In the Ambroxol group 44/52 were extubated and 9/44 (20%) developed BPD. After extubation, RFT showed (i) no statistically significant difference in the ventilatory parameters of either treatment group, (ii) improved (P<0.05) lung mechanics (VT/maxPes) in Ambroxol group compared to controls (94+/-27 ml kPa(-1) vs. 8.1+/-2.6 ml kPa(-1)) and (iii) no statistically significant difference in lung function between infants with and without BPD. At day 28 we found (i) no effect of early Ambroxol treatment on lung functions, (ii) significantly (P < 0.05) higher f (58.5+/-11.7 min(-1) vs. 49.7+/-10.1 min(-1)) and significantly (P<0.01) lower V(T) (9.6+/-1.9 ml vs. 12.3+/-2.7 ml) and V(T)/maxPes (8.9+/-2.6 ml kPa(-1)] vs. 12.0+/-2.9 ml kPa(-1)) in infants with BPD compared to infants without and (iii) these differences are not influenced by early Ambroxol treatment. If the process of BPD development is induced, early Ambroxol treatment has no influence on impaired lung function at day 28.  (+info)

Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia. (3/452)

Ventilator-dependent premature infants are often treated with dexamethasone. Several trials showed that steroids while improve pulmonary compliance and facilitate extubation, some treated infants may have adverse effects, such as alterations of growth curves. We conducted this retrospective study to evaluate the effects of steroids on mechanical ventilation, oxygen therapy, hospital length stay and mortality, in ventilator-dependent infants with bronchopulmonary dysplasia (BPD) (defined as the need of oxygen supplementation at 28 days of life). Twenty-six newborns with BPD were evaluated during 9 - 42 days postpartum (mean = 31 days) and were divided into two groups: Group I - 14 newborns that did not receive dexamethasone, and Group II - 12 newborns that received dexamethasone at 14 - 21 days of life. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously for 3 days, after which the dose was tapered. RESULTS: There were no statistically significant differences in the mean length of mechanical ventilation (Group I - 37 days, Group II - 35 days); oxygen supplementation (Group I - 16 days, Group II - 29 days); hospital stay (Group I - 72 days, Group II - 113 days); mortality (Group I - 35.7%, Group II - 41.6%). At birth, Group II was lighter (BW: Group I - 1154 grams +/- 302, Group II - 791 grams +/- 165; p < 0.05) and smaller (height: Group I - 37.22 cm +/- 3.3, Group II - 33.5 +/- 2.4; p< 0.05) than Group I. At 40 weeks, there were no statistically significant differences between groups in relation to anthropometric measurements. CONCLUSIONS: The use of corticosteroids in bronchopulmonary dysplasic infants may influence the somatic growth during its use. However, after its suspension, a recovery seems to occur, suggesting that its influence could be transitory.  (+info)

Cytokine response during hyperoxia: sequential production of pulmonary tumor necrosis factor and interleukin-6 in neonatal rats. (4/452)

BACKGROUND: Exposure of newborn animals to high concentrations of oxygen leads to diffuse alveolar damage similar to that seen in bronchopulmonary dysplasia in human infants. Therefore, neonatal rats are a suitable practical model of hyperoxic lung damage in human infants. OBJECTIVE: To determine the involvement of tumor necrosis factor-alpha and interleukin-6 in lung injury in neonatal rats exposed to 100% O2 concentration. METHODS: A randomized controlled study was designed in which litters of term Sprague-Dawley rat pups were assigned to experimental or control groups. The pups in the experimental group were placed in 100% O2 from birth for 9 days, while the control pups were placed in room air. Twelve to 15 pups from each group were sacrificed on day 1, 3, 6, 9 and 13 after birth for bronchoalveolar lavage collection and lung histologic study. The bronchoalveolar lavage fluid was assayed for TNF alpha and IL-6. RESULTS: Newborn rats exposed to 100% O2 for the first 9 days of life showed severe pulmonary edema and hypercellularity on days 1 and 3, which then improved to nearly complete resolution on days 6 and 9. Pulmonary TNF alpha was produced early on O2 exposure (day 3) and pulmonary IL-6 later (days 6 and 9). CONCLUSIONS: Hyperoxia induces sequential production of pulmonary TNF alpha and IL-6, which corresponds to the severity of the pathological findings and the known inflammatory and anti-inflammatory role of these cytokines.  (+info)

Birth weight <1501 g and respiratory health at age 14. (5/452)

AIMS: To determine the respiratory health in adolescence of children of birth weight <1501 g, and to compare the results with normal birthweight controls. METHODS: Prospective cohort study of children born in the Royal Women's Hospital, Melbourne. Two cohorts of preterm children (86 consecutive survivors 500-999 g birth weight, and 124 consecutive survivors 1000-1500 g birth weight) and a control group of 60 randomly selected children >2499 g birth weight were studied. Children were assessed at 14 years of age. A paediatrician determined the clinical respiratory status. Lung function was measured according to standard guidelines. RESULTS: Of 180 preterm children seen at age 14, 42 (23%) had bronchopulmonary dysplasia (BPD) in the newborn period. Readmission to hospital for respiratory ill health was infrequent in all groups and the rates of asthma were similar (15% in the 500-999 g birth weight group, 21% in the 1000-1500 g birth weight group, 21% in controls; 19% BPD, 18% no BPD). Overall, lung function was mostly within the normal range for all cohorts; few children had lung function abnormalities in clinically significant ranges. However, the preterm children had significantly lower values for variables reflecting flow. Lung function in children of 500-999 g birth weight was similar to children of 1000-1500 g birth weight. Preterm children with BPD had significantly lower values for variables reflecting flow than children without BPD. CONCLUSIONS: The respiratory health of children of birth weight <1501 g at 14 years of age is comparable to that of term controls.  (+info)

Chronic pulmonary insufficiency in children and its effects on growth and development. (6/452)

Conditions leading to chronic pulmonary insufficiency can affect infants and children. These can lead to growth failure and delayed development. Among the most common and severe of these are bronchopulmonary dysplasia (BPD) and cystic fibrosis. In addition to the respiratory consequences of these diseases, there is ample evidence that they lead to decreased growth as a result of decreased energy intake and increased energy expenditure. Furthermore, there is evidence that infants with BPD may also have delayed development, independent of the effects of their prematurity. Enhancing the long-term outlook for these conditions may therefore require consideration of both improved pulmonary management and aggressive nutritional management to limit growth failure and potentially enhance developmental outcome. Specific micronutrient supplementation, such as antioxidant therapy, may also enhance pulmonary and nutritional status.  (+info)

Special nutritional needs of infants for prevention of and recovery from bronchopulmonary dysplasia. (7/452)

Extremely low birth weight infants who develop severe respiratory disease may have special nutrient requirements imposed by a combination of enhanced utilization of nutrients or the need for epithelial cell repair resulting from the disease process, as well as to support catch-up growth. Inositol, free fatty acids, vitamin E and vitamin A are proposed as nutrients for which infants at risk of chronic pulmonary insufficiency may have special requirements. Of these nutrients, only for vitamin A does suggestive evidence exist that high doses when given intramuscularly may reduce the incidence of death or chronic lung disease. Exogenous steroid therapy (dexamethasone), which is often used to improve pulmonary compliance in ventilated premature infants, may compromise vitamin A status and induce restricted somatic and bone mineral growth. Supplemental nutrition by means of enriched infant formulas has provided benefits in growth and bone mass accretion to infants recovering from bronchopulmonary dysplasia up to 3-mo corrected age. This growth advantage was not sustained over the subsequent 9 mo, suggesting that prolonged nutritional support is required until catch-up growth is complete. Further studies are required to delineate the needs for specific nutrients such as antioxidant vitamins and minerals or vitamin A that may play a role in preventing severe chronic lung disease in premature infants. As well, the role of supplemental nutrition (beyond the requirements of term infants) to support catch-up growth and maintenance during the critical stages of early development requires further investigation before evidence-based nutrient recommendations can be developed for this special population of infants.  (+info)

Is there a role for antioxidant therapy in bronchopulmonary dysplasia? (8/452)

Bronchopulmonary dysplasia (BPD) is a chronic lung disease first described in 1967 as a complication of therapy for premature infants with hyaline membrane disease, and treatment with high concentrations of oxygen was thought to be a major contributor to its development. Thus, interventions to enhance lung antioxidants to prevent the development of BPD were considered appropriate therapeutic strategies. In the last decades, advances in the acute care of premature infants has reduced the reliance on therapy with high concentrations of supplemental oxygen. However, the incidence of BPD has not changed significantly. The changing clinical context in which BPD develops begs the question of whether oxidation is important in the development of BPD and, therefore, whether designing interventions enhancing lung antioxidants is still warranted. This review presents evidence that premature infants that will develop BPD have qualitative and quantitative differences in oxidation of lipids and proteins when compared to infants that do not develop BPD. Such differences in oxidation patterns are the most obvious in the first few days of life. The emerging evidence thus supports the concept that the lung injury process leading to the development of BPD occurs within hours to days of delivery and that oxidation is a major contributor to this pathological process. Unfortunately, early attempts at delivery of antioxidants to the lung have not been successful, perhaps because of an inability to deliver antioxidants in a timely manner to the areas in the lung in which deleterious oxidations are occurring. Further research is necessary to determine both the nature and the location of the oxidative events that lead to the development of early lung injury, so that more appropriate and specific antioxidant interventions can be designed.  (+info)

Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants. It is defined as the need for supplemental oxygen at 28 days of life or beyond, due to abnormal development and injury to the lungs.

The condition was first described in the 1960s, following the introduction of mechanical ventilation and high concentrations of oxygen therapy for premature infants with respiratory distress syndrome (RDS). These treatments, while lifesaving, can also cause damage to the delicate lung tissue, leading to BPD.

The pathogenesis of BPD is complex and involves an interplay between genetic factors, prenatal exposures, and postnatal injury from mechanical ventilation and oxygen toxicity. Inflammation, oxidative stress, and impaired lung development contribute to the development of BPD.

Infants with BPD typically have abnormalities in their airways, alveoli (air sacs), and blood vessels in the lungs. These changes can lead to symptoms such as difficulty breathing, wheezing, coughing, and poor growth. Treatment may include oxygen therapy, bronchodilators, corticosteroids, diuretics, and other medications to support lung function and minimize complications.

The prognosis for infants with BPD varies depending on the severity of the disease and associated medical conditions. While some infants recover completely, others may have long-term respiratory problems that require ongoing management.

Allergic bronchopulmonary aspergillosis (ABPA) is a medical condition characterized by an hypersensitivity reaction to the fungus Aspergillus species, most commonly A. fumigatus. It primarily affects the airways and lung tissue. The immune system overreacts to the presence of the fungus, leading to inflammation and damage in the lungs.

The main symptoms of ABPA include wheezing, coughing, production of thick mucus, shortness of breath, and chest tightness. These symptoms are similar to those seen in asthma and other respiratory conditions. Some people with ABPA may also experience fever, weight loss, and fatigue.

Diagnosis of ABPA typically involves a combination of clinical evaluation, imaging studies (such as chest X-rays or CT scans), and laboratory tests (such as blood tests or sputum cultures) to detect the presence of Aspergillus species and elevated levels of certain antibodies.

Treatment for ABPA usually involves a combination of corticosteroids to reduce inflammation and antifungal medications to eradicate the Aspergillus infection. In some cases, immunomodulatory therapies may also be used to help regulate the immune system's response to the fungus.

It is important to note that ABPA can lead to serious complications if left untreated, including bronchiectasis (permanent enlargement of the airways), pulmonary fibrosis (scarring of the lung tissue), and respiratory failure. Therefore, prompt diagnosis and treatment are essential for managing this condition.

A premature infant is a baby born before 37 weeks of gestation. They may face various health challenges because their organs are not fully developed. The earlier a baby is born, the higher the risk of complications. Prematurity can lead to short-term and long-term health issues, such as respiratory distress syndrome, jaundice, anemia, infections, hearing problems, vision problems, developmental delays, and cerebral palsy. Intensive medical care and support are often necessary for premature infants to ensure their survival and optimal growth and development.

A newborn infant is a baby who is within the first 28 days of life. This period is also referred to as the neonatal period. Newborns require specialized care and attention due to their immature bodily systems and increased vulnerability to various health issues. They are closely monitored for signs of well-being, growth, and development during this critical time.

A very low birth weight (VLBW) infant is a baby born weighing less than 1500 grams (3 pounds, 5 ounces). This category includes babies who are extremely preterm (born at or before 28 weeks of gestation) and/or have intrauterine growth restriction. VLBW infants often face significant health challenges, including respiratory distress syndrome, brain bleeds, infections, and feeding difficulties. They may require extended hospital stays in the neonatal intensive care unit (NICU) and have a higher risk of long-term neurodevelopmental impairments compared to infants with normal birth weights.

Hyperoxia is a medical term that refers to an abnormally high concentration of oxygen in the body or in a specific organ or tissue. It is often defined as the partial pressure of oxygen (PaO2) in arterial blood being greater than 100 mmHg.

This condition can occur due to various reasons such as exposure to high concentrations of oxygen during medical treatments, like mechanical ventilation, or due to certain diseases and conditions that cause the body to produce too much oxygen.

While oxygen is essential for human life, excessive levels can be harmful and lead to oxidative stress, which can damage cells and tissues. Hyperoxia has been linked to various complications, including lung injury, retinopathy of prematurity, and impaired wound healing.

A "premature infant" is a newborn delivered before 37 weeks of gestation. They are at greater risk for various health complications and medical conditions compared to full-term infants, due to their immature organ systems and lower birth weight. Some common diseases and health issues that premature infants may face include:

1. Respiratory Distress Syndrome (RDS): A lung disorder caused by the lack of surfactant, a substance that helps keep the lungs inflated. Premature infants, especially those born before 34 weeks, are at higher risk for RDS.
2. Intraventricular Hemorrhage (IVH): Bleeding in the brain's ventricles, which can lead to developmental delays or neurological issues. The risk of IVH is inversely proportional to gestational age, meaning that the earlier the infant is born, the higher the risk.
3. Necrotizing Enterocolitis (NEC): A gastrointestinal disease where the intestinal tissue becomes inflamed and can die. Premature infants are at greater risk for NEC due to their immature digestive systems.
4. Jaundice: A yellowing of the skin and eyes caused by an accumulation of bilirubin, a waste product from broken-down red blood cells. Premature infants may have higher rates of jaundice due to their liver's immaturity.
5. Infections: Premature infants are more susceptible to infections because of their underdeveloped immune systems. Common sources of infection include the mother's genital tract, bloodstream, or hospital environment.
6. Anemia: A condition characterized by a low red blood cell count or insufficient hemoglobin. Premature infants may develop anemia due to frequent blood sampling, rapid growth, or inadequate erythropoietin production.
7. Retinopathy of Prematurity (ROP): An eye disorder affecting premature infants, where abnormal blood vessel growth occurs in the retina. Severe ROP can lead to vision loss or blindness if not treated promptly.
8. Developmental Delays: Premature infants are at risk for developmental delays due to their immature nervous systems and environmental factors such as sensory deprivation or separation from parents.
9. Patent Ductus Arteriosus (PDA): A congenital heart defect where the ductus arteriosus, a blood vessel that connects two major arteries in the fetal heart, fails to close after birth. Premature infants are at higher risk for PDA due to their immature cardiovascular systems.
10. Hypothermia: Premature infants have difficulty maintaining body temperature and are at risk for hypothermia, which can lead to increased metabolic demands, poor feeding, and infection.

Respiratory Distress Syndrome (RDS), Newborn is a common lung disorder in premature infants. It occurs when the lungs lack a substance called surfactant, which helps keep the tiny air sacs in the lungs open. This results in difficulty breathing and oxygenation, causing symptoms such as rapid, shallow breathing, grunting noises, flaring of the nostrils, and retractions (the skin between the ribs pulls in with each breath). RDS is more common in infants born before 34 weeks of gestation and is treated with surfactant replacement therapy, oxygen support, and mechanical ventilation if necessary. In severe cases, it can lead to complications such as bronchopulmonary dysplasia or even death.

An "Extremely Low Birth Weight" (ELBW) infant is a newborn with a birth weight below 1000 grams (2 pounds, 3 ounces), according to the World Health Organization (WHO). This classification is part of the broader category of low birth weight infants, which includes those born weighing less than 2500 grams (about 5.5 pounds). ELBW infants often face significant health challenges due to their prematurity and small size, which can include issues with breathing, feeding, temperature regulation, and potential long-term neurodevelopmental impairments. It is crucial for these infants to receive specialized care in a neonatal intensive care unit (NICU) to optimize their chances of survival and promote healthy development.

Gestational age is the length of time that has passed since the first day of the last menstrual period (LMP) in pregnant women. It is the standard unit used to estimate the age of a pregnancy and is typically expressed in weeks. This measure is used because the exact date of conception is often not known, but the start of the last menstrual period is usually easier to recall.

It's important to note that since ovulation typically occurs around two weeks after the start of the LMP, gestational age is approximately two weeks longer than fetal age, which is the actual time elapsed since conception. Medical professionals use both gestational and fetal age to track the development and growth of the fetus during pregnancy.

Bronchopulmonary sequestration is a rare birth defect of the lungs, in which a mass of abnormal lung tissue develops that doesn't function and isn't connected to the tracheobronchial tree (the airways that lead to the lungs). This means that the abnormal tissue receives its blood supply from an anomalous systemic artery instead of the normal pulmonary circulation. The mass may be located within the lung (intralobar sequestration) or outside the lung (extralobar sequestration), and it can occur on either side of the chest.

Intralobar sequestrations are more common than extralobar sequestrations, accounting for about 75% of cases. They are usually found in adults and are located within a normal lung tissue. Extralobar sequestrations, on the other hand, are typically detected earlier in life (often as an incidental finding during prenatal ultrasound) and are surrounded by their own pleural lining, which can make them appear separate from the normal lung tissue.

Symptoms of bronchopulmonary sequestration may include recurrent respiratory infections, coughing up blood (hemoptysis), shortness of breath, or chest pain. Treatment usually involves surgical removal of the abnormal tissue to prevent complications such as infection, bleeding, or the development of malignancy.

A lung is a pair of spongy, elastic organs in the chest that work together to enable breathing. They are responsible for taking in oxygen and expelling carbon dioxide through the process of respiration. The left lung has two lobes, while the right lung has three lobes. The lungs are protected by the ribcage and are covered by a double-layered membrane called the pleura. The trachea divides into two bronchi, which further divide into smaller bronchioles, leading to millions of tiny air sacs called alveoli, where the exchange of gases occurs.

Ureaplasma infections refer to conditions caused by the colonization or infection with the bacterial species Ureaplasma urealyticum and Ureaplasma parvum, which are commonly found in the genitourinary tract of humans. These bacteria are part of the normal flora but can cause infections under certain circumstances, such as in immunocompromised individuals or when they ascend to sterile sites like the upper respiratory tract or the amniotic fluid during pregnancy.

Ureaplasma infections can lead to a range of clinical manifestations, including urethritis, cystitis, pelvic inflammatory disease, and respiratory tract infections in newborns. However, it is important to note that the causative role of Ureaplasma spp. in many of these conditions is still a subject of debate, as they can also be found in asymptomatic individuals.

Diagnosis of Ureaplasma infections typically involves nucleic acid amplification tests (NAATs) or culture-based methods to detect the presence of the bacteria in clinical samples. Treatment usually consists of antibiotics that target the bacterial species, such as macrolides or fluoroquinolones, although the development of antimicrobial resistance is a growing concern.

Artificial respiration is an emergency procedure that can be used to provide oxygen to a person who is not breathing or is breathing inadequately. It involves manually forcing air into the lungs, either by compressing the chest or using a device to deliver breaths. The goal of artificial respiration is to maintain adequate oxygenation of the body's tissues and organs until the person can breathe on their own or until advanced medical care arrives. Artificial respiration may be used in conjunction with cardiopulmonary resuscitation (CPR) in cases of cardiac arrest.

A Neonatal Intensive Care Unit (NICU) is a specialized hospital unit that provides advanced, intensive care for newborn babies who are born prematurely, critically ill, or have complex medical conditions. The NICU staff includes neonatologists, neonatal nurses, respiratory therapists, and other healthcare professionals trained to provide specialized care for these vulnerable infants.

The NICU is equipped with advanced technology and monitoring systems to support the babies' breathing, heart function, temperature regulation, and nutrition. The unit may include incubators or radiant warmers to maintain the baby's body temperature, ventilators to assist with breathing, and intravenous lines to provide fluids and medications.

NICUs are typically classified into levels based on the complexity of care provided, ranging from Level I (basic care for healthy newborns) to Level IV (the highest level of care for critically ill newborns). The specific services and level of care provided in a NICU may vary depending on the hospital and geographic location.

Oxygen inhalation therapy is a medical treatment that involves the administration of oxygen to a patient through a nasal tube or mask, with the purpose of increasing oxygen concentration in the body. This therapy is used to treat various medical conditions such as chronic obstructive pulmonary disease (COPD), pneumonia, heart failure, and other conditions that cause low levels of oxygen in the blood. The additional oxygen helps to improve tissue oxygenation, reduce work of breathing, and promote overall patient comfort and well-being. Oxygen therapy may be delivered continuously or intermittently, depending on the patient's needs and medical condition.

Fibrous Dysplasia of Bone is a rare, benign bone disorder that is characterized by the replacement of normal bone tissue with fibrous (scar-like) and immature bone tissue. This results in weakened bones that are prone to fractures, deformities, and pain. The condition can affect any bone in the body but most commonly involves the long bones of the legs, arms, and skull. It can occur as an isolated finding or as part of a genetic disorder called McCune-Albright syndrome. The exact cause of fibrous dysplasia is not fully understood, but it is believed to result from a genetic mutation that occurs during early bone development. There is no cure for fibrous dysplasia, and treatment typically focuses on managing symptoms and preventing complications.

An extremely premature infant is a baby born alive before 28 weeks of gestation. This group of infants is at the highest risk for morbidity and mortality among preterm infants. They often require extensive medical support in the neonatal intensive care unit, including mechanical ventilation, surfactant replacement therapy, and total parenteral nutrition. Extremely premature infants are also at increased risk for long-term neurodevelopmental impairments, such as cerebral palsy, intellectual disability, and vision and hearing problems. The survival rate for extremely premature infants has improved in recent decades due to advances in medical technology and care, but these infants remain a vulnerable population that requires close monitoring and specialized treatment.

Ureaplasma urealyticum is a type of bacteria that belongs to the genus Ureaplasma and the family Mycoplasmataceae. It is a non-motile, non-spore forming, microaerophilic organism, which means it requires reduced oxygen levels for growth.

Ureaplasma urealyticum is unique because it can hydrolyze urea to produce ammonia and carbon dioxide, which helps create a more favorable environment for its growth. This bacterium is commonly found in the genitourinary tract of humans and other primates. It can be part of the normal flora but may also cause infections under certain circumstances.

Infections caused by Ureaplasma urealyticum are often associated with the respiratory and urogenital tracts, particularly in premature infants, immunocompromised individuals, or those with underlying medical conditions. The bacterium can lead to various clinical manifestations, such as pneumonia, bronchopulmonary dysplasia, sepsis, meningitis, and urethritis. However, it is important to note that asymptomatic carriage of Ureaplasma urealyticum is also common, making the interpretation of its clinical significance challenging at times.

Diagnosis typically involves nucleic acid amplification tests (NAATs), such as polymerase chain reaction (PCR) assays, to detect the bacterium's genetic material in clinical samples. Treatment usually consists of antibiotics that target mycoplasmas, like macrolides or tetracyclines, but the choice and duration of therapy depend on the patient's age, immune status, and underlying medical conditions.

Chorioamnionitis is a medical condition that refers to the inflammation of the fetal membranes, specifically the chorion and amnion, which make up the membranous sac surrounding the developing fetus in the uterus. This condition is typically caused by a bacterial infection that ascends from the lower genital tract of the mother and infects the amniotic cavity, leading to an inflammatory response.

The symptoms of chorioamnionitis can vary but often include fever, abdominal pain or tenderness, foul-smelling amniotic fluid, and an elevated white blood cell count in the mother's blood. In some cases, it may also be associated with preterm labor and premature rupture of membranes.

Chorioamnionitis can have serious consequences for both the mother and the baby. It can increase the risk of complications such as sepsis, pneumonia, and endometritis in the mother, and may lead to premature birth, respiratory distress syndrome, and brain injury in the newborn. Treatment typically involves administering antibiotics to the mother to help clear the infection and prevent further complications.

Pulmonary surfactants are a complex mixture of lipids and proteins that are produced by the alveolar type II cells in the lungs. They play a crucial role in reducing the surface tension at the air-liquid interface within the alveoli, which helps to prevent collapse of the lungs during expiration. Surfactants also have important immunological functions, such as inhibiting the growth of certain bacteria and modulating the immune response. Deficiency or dysfunction of pulmonary surfactants can lead to respiratory distress syndrome (RDS) in premature infants and other lung diseases.

Respiratory aspiration is defined as the entry of foreign materials (such as food, liquids, or vomit) into the lower respiratory tract during swallowing, which includes the trachea and lungs. This can lead to respiratory complications such as pneumonia, bronchitis, or lung abscesses. Aspiration can occur in individuals with impaired swallowing function due to various conditions like neurological disorders, stroke, or anesthesia.

Pulmonary alveoli, also known as air sacs, are tiny clusters of air-filled pouches located at the end of the bronchioles in the lungs. They play a crucial role in the process of gas exchange during respiration. The thin walls of the alveoli, called alveolar membranes, allow oxygen from inhaled air to pass into the bloodstream and carbon dioxide from the bloodstream to pass into the alveoli to be exhaled out of the body. This vital function enables the lungs to supply oxygen-rich blood to the rest of the body and remove waste products like carbon dioxide.

Neonatal Intensive Care (NIC) is a specialized medical care for newborn babies who are born prematurely, have low birth weight, or have medical conditions that require advanced medical intervention. This can include monitoring and support for breathing, heart function, temperature regulation, and nutrition. NICUs are staffed with healthcare professionals trained in neonatology, nursing, respiratory therapy, and other specialized areas to provide the highest level of care for these vulnerable infants.

The goal of NICU is to stabilize the newborn's condition, treat medical problems, promote growth and development, and support the family throughout the hospitalization and transition to home. The level of care provided in a NICU can vary depending on the severity of the infant's condition, ranging from basic monitoring and support to complex treatments such as mechanical ventilation, surgery, and medication therapy.

In general, NICUs are classified into different levels based on the complexity of care they can provide. Level I NICUs provide basic care for infants born at or near term who require minimal medical intervention. Level II NICUs provide more advanced care for premature or sick newborns who require specialized monitoring and treatment but do not need surgery or complex therapies. Level III NICUs provide the highest level of care, including advanced respiratory support, surgical services, and critical care for critically ill infants with complex medical conditions.

Ectodermal dysplasia (ED) is a group of genetic disorders that affect the development and formation of ectodermal tissues, which include the skin, hair, nails, teeth, and sweat glands. The condition is usually present at birth or appears in early infancy.

The symptoms of ED can vary widely depending on the specific type and severity of the disorder. Common features may include:

* Sparse or absent hair
* Thin, wrinkled, or rough skin
* Abnormal or missing teeth
* Nail abnormalities
* Absent or reduced sweat glands, leading to heat intolerance and problems regulating body temperature
* Ear abnormalities, which can result in hearing loss
* Eye abnormalities

ED is caused by mutations in genes that are involved in the development of ectodermal tissues. Most cases of ED are inherited in an autosomal dominant or autosomal recessive pattern, meaning that a child can inherit the disorder even if only one parent (dominant) or both parents (recessive) carry the mutated gene.

There is no cure for ED, but treatment is focused on managing the symptoms and improving quality of life. This may include measures to maintain body temperature, such as cooling vests or frequent cool baths; dental treatments to replace missing teeth; hearing aids for hearing loss; and skin care regimens to prevent dryness and irritation.

"Papio" is a term used in the field of primatology, specifically for a genus of Old World monkeys known as baboons. It's not typically used in human or medical contexts. Baboons are large monkeys with robust bodies and distinctive dog-like faces. They are native to various parts of Africa and are known for their complex social structures and behaviors.

"Newborn animals" refers to the very young offspring of animals that have recently been born. In medical terminology, newborns are often referred to as "neonates," and they are classified as such from birth until about 28 days of age. During this time period, newborn animals are particularly vulnerable and require close monitoring and care to ensure their survival and healthy development.

The specific needs of newborn animals can vary widely depending on the species, but generally, they require warmth, nutrition, hydration, and protection from harm. In many cases, newborns are unable to regulate their own body temperature or feed themselves, so they rely heavily on their mothers for care and support.

In medical settings, newborn animals may be examined and treated by veterinarians to ensure that they are healthy and receiving the care they need. This can include providing medical interventions such as feeding tubes, antibiotics, or other treatments as needed to address any health issues that arise. Overall, the care and support of newborn animals is an important aspect of animal medicine and conservation efforts.

Lung injury, also known as pulmonary injury, refers to damage or harm caused to the lung tissue, blood vessels, or air sacs (alveoli) in the lungs. This can result from various causes such as infection, trauma, exposure to harmful substances, or systemic diseases. Common types of lung injuries include acute respiratory distress syndrome (ARDS), pneumonia, and chemical pneumonitis. Symptoms may include difficulty breathing, cough, chest pain, and decreased oxygen levels in the blood. Treatment depends on the underlying cause and may include medications, oxygen therapy, or mechanical ventilation.

Developmental bone diseases are a group of medical conditions that affect the growth and development of bones. These diseases are present at birth or develop during childhood and adolescence, when bones are growing rapidly. They can result from genetic mutations, hormonal imbalances, or environmental factors such as poor nutrition.

Some examples of developmental bone diseases include:

1. Osteogenesis imperfecta (OI): Also known as brittle bone disease, OI is a genetic disorder that affects the body's production of collagen, a protein necessary for healthy bones. People with OI have fragile bones that break easily and may also experience other symptoms such as blue sclerae (whites of the eyes), hearing loss, and joint laxity.
2. Achondroplasia: This is the most common form of dwarfism, caused by a genetic mutation that affects bone growth. People with achondroplasia have short limbs and a large head relative to their body size.
3. Rickets: A condition caused by vitamin D deficiency or an inability to absorb or use vitamin D properly. This leads to weak, soft bones that can bow or bend easily, particularly in children.
4. Fibrous dysplasia: A rare bone disorder where normal bone is replaced with fibrous tissue, leading to weakened bones and deformities.
5. Scoliosis: An abnormal curvature of the spine that can develop during childhood or adolescence. While not strictly a developmental bone disease, scoliosis can be caused by various underlying conditions such as cerebral palsy, muscular dystrophy, or spina bifida.

Treatment for developmental bone diseases varies depending on the specific condition and its severity. Treatment may include medication, physical therapy, bracing, or surgery to correct deformities and improve function. Regular follow-up with a healthcare provider is essential to monitor growth, manage symptoms, and prevent complications.

Ureaplasma is a genus of bacteria that are commonly found in the lower reproductive tract of humans. They belong to the family Mycoplasmataceae and are characterized by their small size and lack of a cell wall. Ureaplasmas are unique because they have the ability to metabolize urea, which they use as a source of energy for growth.

There are several species of Ureaplasma that can infect humans, including Ureaplasma urealyticum and Ureaplasma parvum. These bacteria can cause a variety of clinical syndromes, particularly in individuals with compromised immune systems or underlying respiratory or genitourinary tract disorders.

Infections caused by Ureaplasma are often asymptomatic but can lead to complications such as urethritis, cervicitis, pelvic inflammatory disease, and pneumonia. In newborns, Ureaplasma infections have been associated with bronchopulmonary dysplasia, a chronic lung disorder that can lead to long-term respiratory problems.

Diagnosis of Ureaplasma infections typically involves the use of nucleic acid amplification tests (NAATs) such as polymerase chain reaction (PCR) assays. Treatment usually consists of antibiotics such as macrolides or fluoroquinolones, which are effective against these bacteria.

Lung diseases refer to a broad category of disorders that affect the lungs and other structures within the respiratory system. These diseases can impair lung function, leading to symptoms such as coughing, shortness of breath, chest pain, and wheezing. They can be categorized into several types based on the underlying cause and nature of the disease process. Some common examples include:

1. Obstructive lung diseases: These are characterized by narrowing or blockage of the airways, making it difficult to breathe out. Examples include chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, and cystic fibrosis.
2. Restrictive lung diseases: These involve stiffening or scarring of the lungs, which reduces their ability to expand and take in air. Examples include idiopathic pulmonary fibrosis, sarcoidosis, and asbestosis.
3. Infectious lung diseases: These are caused by bacteria, viruses, fungi, or parasites that infect the lungs. Examples include pneumonia, tuberculosis, and influenza.
4. Vascular lung diseases: These affect the blood vessels in the lungs, impairing oxygen exchange. Examples include pulmonary embolism, pulmonary hypertension, and chronic thromboembolic pulmonary hypertension (CTEPH).
5. Neoplastic lung diseases: These involve abnormal growth of cells within the lungs, leading to cancer. Examples include small cell lung cancer, non-small cell lung cancer, and mesothelioma.
6. Other lung diseases: These include interstitial lung diseases, pleural effusions, and rare disorders such as pulmonary alveolar proteinosis and lymphangioleiomyomatosis (LAM).

It is important to note that this list is not exhaustive, and there are many other conditions that can affect the lungs. Proper diagnosis and treatment of lung diseases require consultation with a healthcare professional, such as a pulmonologist or respiratory therapist.

Periventricular leukomalacia (PVL) is a medical condition that refers to the damage and softening (leukomalacia) of white matter in the brain around the ventricles, which are fluid-filled spaces near the center of the brain. This damage primarily affects the preterm infants, particularly those born before 32 weeks of gestation and weighing less than 1500 grams.

PVL is caused by a decrease in blood flow and oxygen to the periventricular area of the brain, leading to the death of brain cells (infarction) and subsequent scarring (gliosis). The damage to the white matter can result in various neurological problems such as cerebral palsy, developmental delays, visual impairments, and hearing difficulties.

The severity of PVL can vary from mild to severe, with more severe cases resulting in significant neurological deficits. The diagnosis is typically made through imaging techniques like ultrasound, CT, or MRI scans. Currently, there is no specific treatment for PVL, and management focuses on addressing the symptoms and preventing further complications.

Low birth weight is a term used to describe babies who are born weighing less than 5 pounds, 8 ounces (2,500 grams). It's often defined as a birth weight of 2,499 grams or less. This can be further categorized into very low birth weight (less than 1,500 grams) and extremely low birth weight (less than 1,000 grams). Low birth weight is most commonly caused by premature birth, but it can also be caused by growth restriction in the womb. These babies are at risk for numerous health complications, both in the short and long term.

Developmental disabilities are a group of conditions that arise in childhood and are characterized by significant impairments in cognitive functioning, physical development, or both. These disabilities can affect various areas of an individual's life, including their ability to learn, communicate, socialize, and take care of themselves.

Examples of developmental disabilities include intellectual disabilities, cerebral palsy, autism spectrum disorder, Down syndrome, and fetal alcohol spectrum disorders. These conditions are typically diagnosed in childhood and can persist throughout an individual's life.

The causes of developmental disabilities are varied and can include genetic factors, environmental influences, and complications during pregnancy or childbirth. In some cases, the exact cause may be unknown.

It is important to note that individuals with developmental disabilities have unique strengths and abilities, as well as challenges. With appropriate support and services, they can lead fulfilling lives and participate actively in their communities.

Ambroxol is a medication that belongs to the class of drugs known as mucolytic agents or expectorants. It works by thinning and loosening mucus in the airways, making it easier to cough up and clear the airways. This can help reduce symptoms such as chest congestion and shortness of breath in conditions such as chronic bronchitis, bronchiectasis, and cystic fibrosis.

Ambroxol also has some additional properties that make it useful in treating respiratory conditions. It can help to reduce inflammation in the airways, reduce the production of reactive oxygen species (which can damage cells), and increase the activity of certain immune cells that help to fight infection. These effects may contribute to the overall benefits of ambroxol in managing respiratory diseases.

It is important to note that ambroxol should only be used under the guidance of a healthcare professional, as it can have side effects and interactions with other medications. The dosage and duration of treatment will depend on various factors, including the underlying condition being treated, the patient's age and overall health status, and any other medical conditions or medications they may be taking.

The trachea, also known as the windpipe, is a tube-like structure in the respiratory system that connects the larynx (voice box) to the bronchi (the two branches leading to each lung). It is composed of several incomplete rings of cartilage and smooth muscle, which provide support and flexibility. The trachea plays a crucial role in directing incoming air to the lungs during inspiration and outgoing air to the larynx during expiration.

Retinopathy of Prematurity (ROP) is a potentially sight-threatening proliferative retinal vascular disorder that primarily affects prematurely born infants, particularly those with low birth weight and/or young gestational age. It is characterized by the abnormal growth and development of retinal blood vessels due to disturbances in the oxygen supply and metabolic demands during critical phases of fetal development.

The condition can be classified into various stages (1-5) based on its severity, with stages 4 and 5 being more severe forms that may lead to retinal detachment and blindness if left untreated. The pathogenesis of ROP involves an initial phase of vessel loss and regression in the central retina, followed by a secondary phase of abnormal neovascularization, which can cause fibrosis, traction, and ultimately, retinal detachment.

ROP is typically managed with a multidisciplinary approach involving ophthalmologists, neonatologists, and pediatricians. Treatment options include laser photocoagulation, cryotherapy, intravitreal anti-VEGF injections, or even surgical interventions to prevent retinal detachment and preserve vision. Regular screening examinations are crucial for early detection and timely management of ROP in at-risk infants.

'Aspergillus fumigatus' is a species of fungi that belongs to the genus Aspergillus. It is a ubiquitous mold that is commonly found in decaying organic matter, such as leaf litter, compost, and rotting vegetation. This fungus is also known to be present in indoor environments, including air conditioning systems, dust, and water-damaged buildings.

Aspergillus fumigatus is an opportunistic pathogen, which means that it can cause infections in people with weakened immune systems. It can lead to a range of conditions known as aspergillosis, including allergic reactions, lung infections, and invasive infections that can spread to other parts of the body.

The fungus produces small, airborne spores that can be inhaled into the lungs, where they can cause infection. In healthy individuals, the immune system is usually able to eliminate the spores before they can cause harm. However, in people with weakened immune systems, such as those undergoing chemotherapy or organ transplantation, or those with certain underlying medical conditions like asthma or cystic fibrosis, the fungus can establish an infection.

Infections caused by Aspergillus fumigatus can be difficult to treat, and treatment options may include antifungal medications, surgery, or a combination of both. Prompt diagnosis and treatment are essential for improving outcomes in people with aspergillosis.

"Sucking behavior" is not a term typically used in medical terminology. However, in the context of early childhood development and behavior, "non-nutritive sucking" is a term that may be used to describe an infant or young child's habitual sucking on their thumb, fingers, or pacifiers, beyond what is necessary for feeding. This type of sucking behavior can provide a sense of security, comfort, or help to self-soothe and manage stress or anxiety.

It's important to note that while non-nutritive sucking is generally considered a normal part of early childhood development, persistent sucking habits beyond the age of 2-4 years may lead to dental or orthodontic problems such as an overbite or open bite. Therefore, it's recommended to monitor and address these behaviors if they persist beyond this age range.

Apnea is a medical condition defined as the cessation of breathing for 10 seconds or more. It can occur during sleep (sleep apnea) or while awake (wakeful apnea). There are different types of sleep apnea, including obstructive sleep apnea, central sleep apnea, and complex sleep apnea syndrome. Obstructive sleep apnea occurs when the airway becomes blocked during sleep, while central sleep apnea occurs when the brain fails to signal the muscles to breathe. Complex sleep apnea syndrome, also known as treatment-emergent central sleep apnea, is a combination of obstructive and central sleep apneas. Sleep apnea can lead to various complications, such as fatigue, difficulty concentrating, high blood pressure, heart disease, and stroke.

Consensus Development Conferences, NIH are meetings organized by the National Institutes of Health (NIH) to bring together experts in a particular medical field to review and discuss current scientific evidence related to a specific medical topic or controversy. The goal of these conferences is to reach a consensus on the state of the science, identify gaps in knowledge, and provide recommendations for future research and clinical practice.

The conferences are typically conducted over a period of two to three days and include presentations by experts, panel discussions, and open meetings with audience participation. The final consensus statement is developed by a panel of experts who review and synthesize the evidence presented during the conference and provide recommendations based on their collective expertise and judgment.

The consensus development conferences are an important mechanism for disseminating new knowledge and providing guidance to healthcare professionals, patients, and policymakers on controversial or evolving medical issues. They also help to identify priorities for future research and inform the development of clinical practice guidelines and other evidence-based resources.

Patent Ductus Arteriosus (PDA) is a congenital heart defect in which the ductus arteriosus, a normal fetal blood vessel that connects the pulmonary artery and the aorta, fails to close after birth. The ductus arteriosus allows blood to bypass the lungs while the fetus is still in the womb, but it should close shortly after birth as the newborn begins to breathe and oxygenate their own blood.

If the ductus arteriosus remains open or "patent," it can result in abnormal blood flow between the pulmonary artery and aorta. This can lead to various cardiovascular complications, such as:

1. Pulmonary hypertension (high blood pressure in the lungs)
2. Congestive heart failure
3. Increased risk of respiratory infections

The severity of the symptoms and the need for treatment depend on the size of the PDA and the amount of blood flow that is shunted from the aorta to the pulmonary artery. Small PDAs may close on their own over time, while larger PDAs typically require medical intervention, such as medication or surgical closure.

The Apgar score is a quick assessment of the physical condition of a newborn infant, assessed by measuring heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. It is named after Virginia Apgar, an American anesthesiologist who developed it in 1952. The score is usually given at one minute and five minutes after birth, with a possible range of 0 to 10. Scores of 7 and above are considered normal, while scores of 4-6 indicate moderate distress, and scores below 4 indicate severe distress. The Apgar score can provide important information for making decisions about the need for resuscitation or other medical interventions after birth.

A premature birth is defined as the delivery of a baby before 37 weeks of gestation. This can occur spontaneously or as a result of medical intervention due to maternal or fetal complications. Premature babies, also known as preemies, may face various health challenges depending on how early they are born and their weight at birth. These challenges can include respiratory distress syndrome, jaundice, anemia, issues with feeding and digestion, developmental delays, and vision problems. With advancements in medical care and neonatal intensive care units (NICUs), many premature babies survive and go on to lead healthy lives.

Hyaline Membrane Disease (HMD) is a medical condition primarily seen in newborns, also known as Infant Respiratory Distress Syndrome (IRDS). It's characterized by the presence of hyaline membranes, which are made up of proteins and cellular debris, on the inside surfaces of the alveoli (air sacs) in the lungs.

These membranes can interfere with the normal gas exchange process, making it difficult for the newborn to breathe effectively. The condition is often associated with premature birth, as the surfactant that coats the inside of the lungs and keeps them inflated isn't fully produced until around the 35th week of gestation.

The lack of sufficient surfactant can lead to collapse of the alveoli (atelectasis), inflammation, and the formation of hyaline membranes. HMD is a significant cause of morbidity and mortality in premature infants, but with early detection and proper medical care, including the use of artificial surfactant, oxygen therapy, and mechanical ventilation, many babies can recover.

Birth weight refers to the first weight of a newborn infant, usually taken immediately after birth. It is a critical vital sign that indicates the baby's health status and is used as a predictor for various short-term and long-term health outcomes.

Typically, a full-term newborn's weight ranges from 5.5 to 8.8 pounds (2.5 to 4 kg), although normal birth weights can vary significantly based on factors such as gestational age, genetics, maternal health, and nutrition. Low birth weight is defined as less than 5.5 pounds (2.5 kg), while high birth weight is greater than 8.8 pounds (4 kg).

Low birth weight babies are at a higher risk for various medical complications, including respiratory distress syndrome, jaundice, infections, and developmental delays. High birth weight babies may face challenges with delivery, increased risk of obesity, and potential metabolic issues later in life. Regular prenatal care is essential to monitor fetal growth and ensure a healthy pregnancy and optimal birth weight for the baby.

A pressure transducer is a device that converts a mechanical force or pressure exerted upon it into an electrical signal which can be measured and standardized. In medical terms, pressure transducers are often used to measure various bodily pressures such as blood pressure, intracranial pressure, or intraocular pressure. These transducers typically consist of a diaphragm that is deflected by the pressure being measured, which then generates an electrical signal proportional to the amount of deflection. This signal can be processed and displayed in various ways, such as on a monitor or within an electronic medical record system.

Maximal Expiratory Flow Rate (MEFR) is a measure of how quickly a person can exhale air from their lungs. It is often used in pulmonary function testing to assess the degree of airflow obstruction in conditions such as chronic obstructive pulmonary disease (COPD) or asthma.

The MEFR is typically measured by having the person take a deep breath and then exhale as forcefully and quickly as possible into a device that measures the volume and flow of air. The MEFR is calculated as the maximum flow rate achieved during the exhalation maneuver, usually expressed in liters per second (L/s) or seconds (L/sec).

MEFR can be measured at different lung volumes, such as at functional residual capacity (FRC) or at total lung capacity (TLC), to provide additional information about the severity and location of airflow obstruction. However, MEFR is not as commonly used in clinical practice as other measures of pulmonary function, such as forced expiratory volume in one second (FEV1) or forced vital capacity (FVC).

Pregnancy is a physiological state or condition where a fertilized egg (zygote) successfully implants and grows in the uterus of a woman, leading to the development of an embryo and finally a fetus. This process typically spans approximately 40 weeks, divided into three trimesters, and culminates in childbirth. Throughout this period, numerous hormonal and physical changes occur to support the growing offspring, including uterine enlargement, breast development, and various maternal adaptations to ensure the fetus's optimal growth and well-being.

Functional Residual Capacity (FRC) is the volume of air that remains in the lungs after normal expiration during quiet breathing. It represents the sum of the residual volume (RV) and the expiratory reserve volume (ERV). The FRC is approximately 2.5-3.5 liters in a healthy adult. This volume of air serves to keep the alveoli open and maintain oxygenation during periods of quiet breathing, as well as providing a reservoir for additional ventilation during increased activity or exercise.

Uterine cervical dysplasia is a condition characterized by abnormal cell growth on the lining of the cervix, which is the lower part of the uterus that connects to the vagina. It is also known as cervical intraepithelial neoplasia (CIN).

Cervical dysplasia can be caused by certain strains of human papillomavirus (HPV), a common sexually transmitted infection. The abnormal cells may develop into cancerous cells over time, although not all cases of cervical dysplasia will progress to cancer.

Cervical dysplasia is typically detected through a Pap test or HPV test, which are screening tests used to detect precancerous changes in the cervix. Depending on the severity and extent of the abnormal cells, treatment options may include close monitoring, surgical removal of the affected tissue, or more extensive surgery.

It is important for women to receive regular Pap tests and HPV tests as recommended by their healthcare provider to detect and treat cervical dysplasia early, before it has a chance to progress to cancer.

Dexamethasone is a type of corticosteroid medication, which is a synthetic version of a natural hormone produced by the adrenal glands. It is often used to reduce inflammation and suppress the immune system in a variety of medical conditions, including allergies, asthma, rheumatoid arthritis, and certain skin conditions.

Dexamethasone works by binding to specific receptors in cells, which triggers a range of anti-inflammatory effects. These include reducing the production of chemicals that cause inflammation, suppressing the activity of immune cells, and stabilizing cell membranes.

In addition to its anti-inflammatory effects, dexamethasone can also be used to treat other medical conditions, such as certain types of cancer, brain swelling, and adrenal insufficiency. It is available in a variety of forms, including tablets, liquids, creams, and injectable solutions.

Like all medications, dexamethasone can have side effects, particularly if used for long periods of time or at high doses. These may include mood changes, increased appetite, weight gain, acne, thinning skin, easy bruising, and an increased risk of infections. It is important to follow the instructions of a healthcare provider when taking dexamethasone to minimize the risk of side effects.

Bronchial diseases refer to medical conditions that affect the bronchi, which are the large airways that lead into the lungs. These diseases can cause inflammation, narrowing, or obstruction of the bronchi, leading to symptoms such as coughing, wheezing, chest tightness, and difficulty breathing.

Some common bronchial diseases include:

1. Asthma: A chronic inflammatory disease of the airways that causes recurring episodes of wheezing, breathlessness, chest tightness, and coughing.
2. Chronic Bronchitis: A long-term inflammation of the bronchi that leads to a persistent cough and excessive mucus production.
3. Bronchiectasis: A condition in which the bronchi become damaged and widened, leading to chronic infection and inflammation.
4. Bronchitis: An inflammation of the bronchi that can cause coughing, wheezing, and chest tightness.
5. Emphysema: A lung condition that causes shortness of breath due to damage to the air sacs in the lungs. While not strictly a bronchial disease, it is often associated with chronic bronchitis and COPD (Chronic Obstructive Pulmonary Disease).

Treatment for bronchial diseases may include medications such as bronchodilators, corticosteroids, or antibiotics, as well as lifestyle changes such as quitting smoking and avoiding irritants. In severe cases, oxygen therapy or surgery may be necessary.

Fibromuscular dysplasia (FMD) is a rare condition that affects the arterial walls, primarily in the medium and large-sized arteries. According to the American Heart Association, FMD is characterized by uneven growth or damage to the cells in the artery wall, leading to the formation of fibrous tissue and areas with narrowing (stenosis) or ballooning (aneurysm) of the artery.

FMD most commonly affects the renal (kidney) and carotid (neck) arteries but can also occur in other arteries, such as those in the abdomen, arms, and legs. The exact cause of FMD is unknown, but genetic factors and hormonal influences are believed to play a role.

Symptoms of FMD depend on which arteries are affected and may include high blood pressure, headaches, neck pain, dizziness, visual disturbances, or kidney problems. Diagnosis typically involves imaging tests like ultrasound, CT angiography, or magnetic resonance angiography (MRA). Treatment options for FMD include medications to manage symptoms and control high blood pressure, as well as various interventions such as angioplasty or stenting to open narrowed arteries.

Pneumocytes are specialized epithelial cells that line the alveoli, which are the tiny air sacs in the lungs where gas exchange occurs. There are two main types of pneumocytes: type I and type II.

Type I pneumocytes are flat, thin cells that cover about 95% of the alveolar surface area. They play a crucial role in facilitating the diffusion of oxygen and carbon dioxide between the alveoli and the bloodstream. Type I pneumocytes also contribute to maintaining the structural integrity of the alveoli.

Type II pneumocytes are smaller, more cuboidal cells that produce and secrete surfactant, a substance composed of proteins and lipids that reduces surface tension within the alveoli, preventing their collapse and facilitating breathing. Type II pneumocytes can also function as progenitor cells, capable of differentiating into type I pneumocytes to help repair damaged lung tissue.

In summary, pneumocytes are essential for maintaining proper gas exchange in the lungs and contributing to the overall health and functioning of the respiratory system.

Gastrointestinal (GI) contents refer to the physical substances within the gastrointestinal tract, which includes the stomach, small intestine, and large intestine. These contents can vary depending on the time since the last meal and the digestive process that is underway. Generally, GI contents include food, fluids, digestive enzymes, secretions, bacteria, and other waste products.

In a more specific context, GI contents may also refer to the stomach contents, which are often analyzed during autopsies or in cases of suspected poisoning or overdose. Stomach contents can provide valuable information about the type and amount of substances that have been ingested within a few hours prior to the analysis.

It is important to note that GI contents should not be confused with gastrointestinal fluids, which specifically refer to the secretions produced by the gastrointestinal tract, such as gastric juice in the stomach or bile in the small intestine.

Intermittent Positive-Pressure Ventilation (IPPV) is a type of mechanical ventilation in which positive pressure is intermittently applied to the airway and lungs, allowing for inflation and deflation of the lungs. This mode of ventilation is often used in critical care settings such as intensive care units (ICUs) to support patients who are unable to breathe effectively on their own due to respiratory failure or other conditions that affect breathing.

During IPPV, a mechanical ventilator delivers breaths to the patient at set intervals, with each breath consisting of a set volume or pressure. The patient may also be allowed to take spontaneous breaths between the mechanically delivered breaths. The settings for IPPV can be adjusted based on the patient's needs and condition, including factors such as their respiratory rate, tidal volume (the amount of air moved with each breath), and positive end-expiratory pressure (PEEP), which helps to keep the alveoli open and prevent atelectasis.

IPPV can be used to provide short-term or long-term ventilatory support, depending on the patient's needs. It is an effective way to ensure that patients receive adequate oxygenation and ventilation while minimizing the risk of lung injury associated with high pressures or volumes. However, it is important to closely monitor patients receiving IPPV and adjust the settings as needed to avoid complications such as ventilator-associated pneumonia or barotrauma.

Continuous Positive Airway Pressure (CPAP) is a mode of non-invasive ventilation that delivers pressurized room air or oxygen to maintain airway patency and increase functional residual capacity in patients with respiratory disorders. A CPAP device, which typically includes a flow generator, tubing, and a mask, provides a constant positive pressure throughout the entire respiratory cycle, preventing the collapse of the upper airway during inspiration and expiration.

CPAP is commonly used to treat obstructive sleep apnea (OSA), a condition characterized by repetitive narrowing or closure of the upper airway during sleep, leading to intermittent hypoxia, hypercapnia, and sleep fragmentation. By delivering positive pressure, CPAP helps to stent open the airway, ensuring unobstructed breathing and reducing the frequency and severity of apneic events.

Additionally, CPAP can be used in other clinical scenarios, such as managing acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD) exacerbations, or postoperative respiratory insufficiency, to improve oxygenation and reduce the work of breathing. The specific pressure settings and device configurations are tailored to each patient's needs based on their underlying condition, severity of symptoms, and response to therapy.

In medical terms, suction refers to the process of creating and maintaining a partial vacuum in order to remove fluids or gases from a body cavity or wound. This is typically accomplished using specialized medical equipment such as a suction machine, which uses a pump to create the vacuum, and a variety of different suction tips or catheters that can be inserted into the area being treated.

Suction is used in a wide range of medical procedures and treatments, including wound care, surgical procedures, respiratory therapy, and diagnostic tests. It can help to remove excess fluids such as blood or pus from a wound, clear secretions from the airways during mechanical ventilation, or provide a means of visualizing internal structures during endoscopic procedures.

It is important to use proper technique when performing suctioning, as excessive or improperly applied suction can cause tissue damage or bleeding. Medical professionals are trained in the safe and effective use of suction equipment and techniques to minimize risks and ensure optimal patient outcomes.

Psychomotor disorders are conditions that involve abnormalities in cognition, emotion, and behavior associated with impaired voluntary motor or movement functions. These disorders can be characterized by hypoactivity (decreased motor activity) or hyperactivity (increased motor activity). Examples of psychomotor disorders include Parkinson's disease, Huntington's disease, Tourette syndrome, and catatonia. Psychomotor agitation, retardation, and stereotypies are also considered psychomotor disorders. These conditions can significantly impact a person's daily functioning and quality of life.

"Inhalation administration" is a medical term that refers to the method of delivering medications or therapeutic agents directly into the lungs by inhaling them through the airways. This route of administration is commonly used for treating respiratory conditions such as asthma, COPD (chronic obstructive pulmonary disease), and cystic fibrosis.

Inhalation administration can be achieved using various devices, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and soft-mist inhalers. Each device has its unique mechanism of delivering the medication into the lungs, but they all aim to provide a high concentration of the drug directly to the site of action while minimizing systemic exposure and side effects.

The advantages of inhalation administration include rapid onset of action, increased local drug concentration, reduced systemic side effects, and improved patient compliance due to the ease of use and non-invasive nature of the delivery method. However, proper technique and device usage are crucial for effective therapy, as incorrect usage may result in suboptimal drug deposition and therapeutic outcomes.

Bronchoalveolar lavage (BAL) fluid is a type of clinical specimen obtained through a procedure called bronchoalveolar lavage. This procedure involves inserting a bronchoscope into the lungs and instilling a small amount of saline solution into a specific area of the lung, then gently aspirating the fluid back out. The fluid that is recovered is called bronchoalveolar lavage fluid.

BAL fluid contains cells and other substances that are present in the lower respiratory tract, including the alveoli (the tiny air sacs where gas exchange occurs). By analyzing BAL fluid, doctors can diagnose various lung conditions, such as pneumonia, interstitial lung disease, and lung cancer. They can also monitor the effectiveness of treatments for these conditions by comparing the composition of BAL fluid before and after treatment.

BAL fluid is typically analyzed for its cellular content, including the number and type of white blood cells present, as well as for the presence of bacteria, viruses, or other microorganisms. The fluid may also be tested for various proteins, enzymes, and other biomarkers that can provide additional information about lung health and disease.

Ventilator weaning is the process of gradually reducing the amount of support provided by a mechanical ventilator to a patient, with the ultimate goal of completely withdrawing the mechanical assistance and allowing the patient to breathe independently. This process is typically initiated when the patient's underlying medical condition has improved to the point where they are able to sustain their own respiratory efforts.

The weaning process may involve reducing the frequency and duration of ventilator breaths, decreasing the amount of oxygen supplied by the ventilator, or adjusting the settings of the ventilator to encourage the patient to take more frequent and deeper breaths on their own. The rate at which weaning is attempted will depend on the individual patient's condition and overall progress.

Close monitoring of the patient's respiratory status, oxygenation, and work of breathing is essential during the weaning process to ensure that the patient is able to tolerate the decreased level of support and to identify any potential complications that may arise. Effective communication between the healthcare team and the patient is also important to provide education, set expectations, and address any concerns or questions that may arise during the weaning process.

Osteochondrodysplasias are a group of genetic disorders that affect the development of bones and cartilage. These conditions can result in dwarfism or short stature, as well as other skeletal abnormalities. Osteochondrodysplasias can be caused by mutations in genes that regulate bone and cartilage growth, and they are often characterized by abnormalities in the shape, size, and/or structure of the bones and cartilage.

There are many different types of osteochondrodysplasias, each with its own specific symptoms and patterns of inheritance. Some common examples include achondroplasia, thanatophoric dysplasia, and spondyloepiphyseal dysplasia. These conditions can vary in severity, and some may be associated with other health problems, such as respiratory difficulties or neurological issues.

Treatment for osteochondrodysplasias typically focuses on managing the symptoms and addressing any related health concerns. This may involve physical therapy, bracing or surgery to correct skeletal abnormalities, and treatment for any associated medical conditions. In some cases, genetic counseling may also be recommended for individuals with osteochondrodysplasias and their families.

I'm sorry for any confusion, but "Portugal" is not a medical term. It is a country located in southwestern Europe, known officially as the Portuguese Republic. If you have any questions about medical terminology or health-related topics, I would be happy to help!

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Fibrous dysplasia, monostotic is a benign bone disorder that affects a single bone (monostotic) and is characterized by the replacement of normal bone tissue with fibrous (scar-like) tissue. This results in the formation of abnormal bone that is weakened and more susceptible to fractures. The lesions can cause deformities, pain, and decreased mobility, depending on their size and location. Monostotic fibrous dysplasia is the most common form of fibrous dysplasia, accounting for approximately 70-80% of all cases. It typically manifests during childhood or adolescence and may stabilize or progress slowly over time. In some cases, it can be associated with endocrine disorders such as precocious puberty, hyperthyroidism, or growth hormone excess.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

Fatty alcohols, also known as long-chain alcohols or long-chain fatty alcohols, are a type of fatty compound that contains a hydroxyl group (-OH) and a long alkyl chain. They are typically derived from natural sources such as plant and animal fats and oils, and can also be synthetically produced.

Fatty alcohols can vary in chain length, typically containing between 8 and 30 carbon atoms. They are commonly used in a variety of industrial and consumer products, including detergents, emulsifiers, lubricants, and personal care products. In the medical field, fatty alcohols may be used as ingredients in certain medications or topical treatments.

Respiratory Function Tests (RFTs) are a group of medical tests that measure how well your lungs take in and exhale air, and how well they transfer oxygen and carbon dioxide into and out of your blood. They can help diagnose certain lung disorders, measure the severity of lung disease, and monitor response to treatment.

RFTs include several types of tests, such as:

1. Spirometry: This test measures how much air you can exhale and how quickly you can do it. It's often used to diagnose and monitor conditions like asthma, chronic obstructive pulmonary disease (COPD), and other lung diseases.
2. Lung volume testing: This test measures the total amount of air in your lungs. It can help diagnose restrictive lung diseases, such as pulmonary fibrosis or sarcoidosis.
3. Diffusion capacity testing: This test measures how well oxygen moves from your lungs into your bloodstream. It's often used to diagnose and monitor conditions like pulmonary fibrosis, interstitial lung disease, and other lung diseases that affect the ability of the lungs to transfer oxygen to the blood.
4. Bronchoprovocation testing: This test involves inhaling a substance that can cause your airways to narrow, such as methacholine or histamine. It's often used to diagnose and monitor asthma.
5. Exercise stress testing: This test measures how well your lungs and heart work together during exercise. It's often used to diagnose lung or heart disease.

Overall, Respiratory Function Tests are an important tool for diagnosing and managing a wide range of lung conditions.

Fibrous Dysplasia, Polyostotic is a rare genetic disorder that affects the bone tissue. It is characterized by the replacement of normal bone tissue with fibrous (scar-like) tissue, leading to weak and fragile bones that are prone to fractures and deformities. The term "polyostotic" refers to the involvement of multiple bones in the body.

In this condition, there is an abnormal development of the bone during fetal growth or early childhood due to a mutation in the GNAS gene. This results in the formation of fibrous tissue instead of normal bone tissue, leading to the characteristic features of Fibrous Dysplasia, Polyostotic.

The symptoms of this condition can vary widely depending on the severity and location of the affected bones. Common symptoms include:

* Bone pain and tenderness
* Bone deformities (such as bowing of the legs)
* Increased risk of fractures
* Skin pigmentation changes (cafe-au-lait spots)
* Hearing loss or other hearing problems (if the skull is affected)

Fibrous Dysplasia, Polyostotic can also be associated with endocrine disorders such as precocious puberty and hyperthyroidism. Treatment typically involves a combination of medications to manage pain and prevent fractures, as well as surgical intervention to correct bone deformities or stabilize fractures.

A fetus is the developing offspring in a mammal, from the end of the embryonic period (approximately 8 weeks after fertilization in humans) until birth. In humans, the fetal stage of development starts from the eleventh week of pregnancy and continues until childbirth, which is termed as full-term pregnancy at around 37 to 40 weeks of gestation. During this time, the organ systems become fully developed and the body grows in size. The fetus is surrounded by the amniotic fluid within the amniotic sac and is connected to the placenta via the umbilical cord, through which it receives nutrients and oxygen from the mother. Regular prenatal care is essential during this period to monitor the growth and development of the fetus and ensure a healthy pregnancy and delivery.

Fungal lung diseases, also known as fungal pneumonia or mycoses, refer to a group of respiratory disorders caused by the infection of fungi in the lungs. These fungi are commonly found in the environment, such as soil, decaying organic matter, and contaminated materials. People can develop lung diseases from fungi after inhaling spores or particles that contain fungi.

There are several types of fungal lung diseases, including:

1. Aspergillosis: This is caused by the Aspergillus fungus and can affect people with weakened immune systems. It can cause allergic reactions, lung infections, or invasive aspergillosis, which can spread to other organs.
2. Cryptococcosis: This is caused by the Cryptococcus fungus and is usually found in soil contaminated with bird droppings. It can cause pneumonia, meningitis, or skin lesions.
3. Histoplasmosis: This is caused by the Histoplasma capsulatum fungus and is commonly found in the Ohio and Mississippi River valleys. It can cause flu-like symptoms, lung infections, or disseminated histoplasmosis, which can spread to other organs.
4. Blastomycosis: This is caused by the Blastomyces dermatitidis fungus and is commonly found in the southeastern and south-central United States. It can cause pneumonia, skin lesions, or disseminated blastomycosis, which can spread to other organs.
5. Coccidioidomycosis: This is caused by the Coccidioides immitis fungus and is commonly found in the southwestern United States. It can cause flu-like symptoms, lung infections, or disseminated coccidioidomycosis, which can spread to other organs.

Fungal lung diseases can range from mild to severe, depending on the type of fungus and the person's immune system. Treatment may include antifungal medications, surgery, or supportive care. Prevention measures include avoiding exposure to contaminated soil or dust, wearing protective masks in high-risk areas, and promptly seeking medical attention if symptoms develop.

Oxygen is a colorless, odorless, tasteless gas that constitutes about 21% of the earth's atmosphere. It is a crucial element for human and most living organisms as it is vital for respiration. Inhaled oxygen enters the lungs and binds to hemoglobin in red blood cells, which carries it to tissues throughout the body where it is used to convert nutrients into energy and carbon dioxide, a waste product that is exhaled.

Medically, supplemental oxygen therapy may be provided to patients with conditions such as chronic obstructive pulmonary disease (COPD), pneumonia, heart failure, or other medical conditions that impair the body's ability to extract sufficient oxygen from the air. Oxygen can be administered through various devices, including nasal cannulas, face masks, and ventilators.

Necrotizing enterocolitis (NEC) is a serious gastrointestinal condition that primarily affects premature infants. It is characterized by the inflammation and death of intestinal tissue, which can lead to perforations (holes) in the bowel wall. Here's a brief medical definition:

Necrotizing enterocolitis (NEK-roh-tiz-ing en-ter-koh-li-TIE-tis): A gastrointestinal emergency in which the inner lining of the intestinal wall undergoes necrosis (tissue death) due to inflammation, often affecting premature infants. The condition may result in bowel perforations, sepsis, and other systemic complications, requiring surgical intervention and intensive care management.

The exact cause of NEC is not fully understood, but it's thought to be associated with factors such as prematurity, formula feeding, intestinal immaturity or injury, and disturbed blood flow in the intestines. Symptoms may include abdominal distention, bloody stools, feeding intolerance, lethargy, and temperature instability. Early recognition and prompt treatment are crucial for improving outcomes in affected infants.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Canine hip dysplasia (CHD) is a common skeletal disorder in dogs, particularly in large and giant breeds, characterized by the abnormal development and degeneration of the coxofemoral joint - the joint where the head of the femur (thigh bone) meets the acetabulum (hip socket) of the pelvis. This condition is often caused by a combination of genetic and environmental factors that lead to laxity (looseness) of the joint, which can result in osteoarthritis (OA), pain, and decreased mobility over time.

In a healthy hip joint, the femoral head fits snugly into the acetabulum, allowing smooth and stable movement. However, in dogs with CHD, the following abnormalities may occur:

1. Shallow acetabulum: The hip socket may not be deep enough to provide adequate coverage of the femoral head, leading to joint instability.
2. Flared acetabulum: The rim of the acetabulum may become stretched and flared due to excessive forces exerted on it by the lax joint.
3. Misshapen or malformed femoral head: The femoral head may not have a normal round shape, further contributing to joint instability.
4. Laxity of the joint: The ligament that holds the femoral head in place within the acetabulum (ligamentum teres) can become stretched, allowing for excessive movement and abnormal wear of the joint surfaces.

These changes can lead to the development of osteoarthritis, which is characterized by the breakdown and loss of cartilage within the joint, as well as the formation of bone spurs (osteophytes) and thickening of the joint capsule. This results in pain, stiffness, and decreased range of motion, making it difficult for affected dogs to perform everyday activities such as walking, running, or climbing stairs.

Canine hip dysplasia is typically diagnosed through a combination of physical examination, medical history, and imaging techniques such as radiographs (X-rays). Treatment options may include conservative management, such as weight management, exercise modification, joint supplements, and pain medication, or surgical intervention, such as total hip replacement. The choice of treatment depends on the severity of the disease, the age and overall health of the dog, and the owner's financial resources.

Preventing canine hip dysplasia is best achieved through selective breeding practices that aim to eliminate affected animals from breeding populations. Additionally, maintaining a healthy weight, providing appropriate exercise, and ensuring proper nutrition throughout a dog's life can help reduce the risk of developing this debilitating condition.

Bronchiectasis is a medical condition characterized by permanent, abnormal widening and thickening of the walls of the bronchi (the airways leading to the lungs). This can lead to recurrent respiratory infections, coughing, and the production of large amounts of sputum. The damage to the airways is usually irreversible and can be caused by various factors such as bacterial or viral infections, genetic disorders, immune deficiencies, or exposure to environmental pollutants. In some cases, the cause may remain unknown. Treatment typically includes chest physiotherapy, bronchodilators, antibiotics, and sometimes surgery.

Cleidocranial dysplasia is a genetic skeletal disorder that affects the development of bones and teeth. The condition is characterized by the underdevelopment or absence of the collarbones (clavicles), which can result in shoulder joints that are abnormally close together. This may allow the person to bring their shoulders around to touch or even overlap in front of their body.

People with cleidocranial dysplasia also often have a delayed closure of the fontanels (soft spots) on the skull, as well as an abnormal shape and size of the head. The facial bones may be underdeveloped, leading to a sunken appearance in the middle of the face and a prominent forehead. Dental abnormalities are also common, such as missing or delayed eruption of teeth, extra teeth, and misaligned teeth.

Cleidocranial dysplasia is caused by mutations in the CBFA1/RUNX2 gene and is inherited in an autosomal dominant manner, meaning that a child has a 50% chance of inheriting the condition if one of their parents is affected. However, many cases result from new mutations in the gene and occur in people with no family history of the disorder. Treatment typically involves surgical procedures to correct skeletal abnormalities and dental issues, as well as orthodontic treatment to align teeth.

Retinal dysplasia is a developmental abnormality of the retina, which is the light-sensitive tissue located at the back of the eye. This condition is characterized by the presence of folds or rosettes (round clusters) in the retinal structure, resulting from improper or disorganized growth of the retinal cells during fetal development.

Retinal dysplasia can be classified into two types:

1. Focal or localized retinal dysplasia: This type is limited to a small area of the retina and usually does not significantly affect vision. It may present as mild folds or rosettes in the retinal structure.
2. Generalized or severe retinal dysplasia: This type involves widespread disorganization of the retinal layers, leading to more significant visual impairment. In extreme cases, it can result in complete detachment of the retina from the underlying tissue, causing blindness.

Retinal dysplasia can be an isolated finding or associated with various genetic disorders, infections, or environmental factors during pregnancy. Depending on the severity and underlying cause, management may include monitoring for visual development, corrective lenses, or treatment of associated conditions.

A "newborn infant" refers to a baby in the first 28 days of life outside of the womb. This period is crucial for growth and development, but also poses unique challenges as the infant's immune system is not fully developed, making them more susceptible to various diseases.

"Newborn diseases" are health conditions that specifically affect newborn infants. These can be categorized into three main types:

1. Congenital disorders: These are conditions that are present at birth and may be inherited or caused by factors such as infection, exposure to harmful substances during pregnancy, or chromosomal abnormalities. Examples include Down syndrome, congenital heart defects, and spina bifida.

2. Infectious diseases: Newborn infants are particularly vulnerable to infections due to their immature immune systems. Common infectious diseases in newborns include sepsis (bloodstream infection), pneumonia, and meningitis. These can be acquired from the mother during pregnancy or childbirth, or from the environment after birth.

3. Developmental disorders: These are conditions that affect the normal growth and development of the newborn infant. Examples include cerebral palsy, intellectual disabilities, and vision or hearing impairments.

It is important to note that many newborn diseases can be prevented or treated with appropriate medical care, including prenatal care, proper hygiene practices, and timely vaccinations. Regular check-ups and monitoring of the newborn's health by a healthcare provider are essential for early detection and management of any potential health issues.

Cerebral palsy (CP) is a group of disorders that affect a person's ability to move and maintain balance and posture. According to the Mayo Clinic, CP is caused by abnormal brain development or damage to the developing brain that affects a child's ability to control movement.

The symptoms of cerebral palsy can vary in severity and may include:

* Spasticity (stiff or tight muscles)
* Rigidity (resistance to passive movement)
* Poor coordination and balance
* Weakness or paralysis
* Tremors or involuntary movements
* Abnormal gait or difficulty walking
* Difficulty with fine motor skills, such as writing or using utensils
* Speech and language difficulties
* Vision, hearing, or swallowing problems

It's important to note that cerebral palsy is not a progressive condition, meaning that it does not worsen over time. However, the symptoms may change over time, and some individuals with CP may experience additional medical conditions as they age.

Cerebral palsy is usually caused by brain damage that occurs before or during birth, but it can also be caused by brain injuries that occur in the first few years of life. Some possible causes of cerebral palsy include:

* Infections during pregnancy
* Lack of oxygen to the brain during delivery
* Traumatic head injury during birth
* Brain bleeding or stroke in the newborn period
* Genetic disorders
* Maternal illness or infection during pregnancy

There is no cure for cerebral palsy, but early intervention and treatment can help improve outcomes and quality of life. Treatment may include physical therapy, occupational therapy, speech therapy, medications to manage symptoms, surgery, and assistive devices such as braces or wheelchairs.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Bronchial neoplasms refer to abnormal growths or tumors in the bronchi, which are the large airways that lead into the lungs. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant bronchial neoplasms are often referred to as lung cancer and can be further classified into small cell lung cancer and non-small cell lung cancer, depending on the type of cells involved.

Benign bronchial neoplasms are less common than malignant ones and may include growths such as papillomas, hamartomas, or chondromas. While benign neoplasms are not cancerous, they can still cause symptoms and complications if they grow large enough to obstruct the airways or if they become infected.

Treatment for bronchial neoplasms depends on several factors, including the type, size, location, and stage of the tumor, as well as the patient's overall health and medical history. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

The adrenal cortex hormones are a group of steroid hormones produced and released by the outer portion (cortex) of the adrenal glands, which are located on top of each kidney. These hormones play crucial roles in regulating various physiological processes, including:

1. Glucose metabolism: Cortisol helps control blood sugar levels by increasing glucose production in the liver and reducing its uptake in peripheral tissues.
2. Protein and fat metabolism: Cortisol promotes protein breakdown and fatty acid mobilization, providing essential building blocks for energy production during stressful situations.
3. Immune response regulation: Cortisol suppresses immune function to prevent overactivation and potential damage to the body during stress.
4. Cardiovascular function: Aldosterone regulates electrolyte balance and blood pressure by promoting sodium reabsorption and potassium excretion in the kidneys.
5. Sex hormone production: The adrenal cortex produces small amounts of sex hormones, such as androgens and estrogens, which contribute to sexual development and function.
6. Growth and development: Cortisol plays a role in normal growth and development by influencing the activity of growth-promoting hormones like insulin-like growth factor 1 (IGF-1).

The main adrenal cortex hormones include:

1. Glucocorticoids: Cortisol is the primary glucocorticoid, responsible for regulating metabolism and stress response.
2. Mineralocorticoids: Aldosterone is the primary mineralocorticoid, involved in electrolyte balance and blood pressure regulation.
3. Androgens: Dehydroepiandrosterone (DHEA) and its sulfate derivative (DHEAS) are the most abundant adrenal androgens, contributing to sexual development and function.
4. Estrogens: Small amounts of estrogens are produced by the adrenal cortex, mainly in women.

Disorders related to impaired adrenal cortex hormone production or regulation can lead to various clinical manifestations, such as Addison's disease (adrenal insufficiency), Cushing's syndrome (hypercortisolism), and congenital adrenal hyperplasia (CAH).

Congenital hip dislocation, also known as developmental dysplasia of the hip (DDH), is a condition where the hip joint fails to develop normally in utero or during early infancy. In a healthy hip, the head of the femur (thigh bone) fits snugly into the acetabulum (hip socket). However, in congenital hip dislocation, the femoral head is not held firmly in place within the acetabulum due to abnormal development or laxity of the ligaments that support the joint.

There are two types of congenital hip dislocations:

1. Teratologic dislocation: This type is present at birth and occurs due to abnormalities in the development of the hip joint during fetal growth. The femoral head may be completely outside the acetabulum or partially dislocated.

2. Developmental dysplasia: This type develops after birth, often within the first few months of life, as a result of ligamentous laxity and shallow acetabulum. In some cases, it can progress to a complete hip dislocation if left untreated.

Risk factors for congenital hip dislocation include family history, breech presentation during delivery, and female gender. Early diagnosis and treatment are crucial to prevent long-term complications such as pain, limited mobility, and osteoarthritis. Treatment options may include bracing, closed reduction, or surgical intervention, depending on the severity and age of the child at diagnosis.

Bronchopulmonary Dysplasia. "Bronchopulmonary Dysplasia". American Lung Association. Retrieved 2020-03-12. Northway Jr, WH; ... "Bronchopulmonary Dysplasia". Patient.info. Retrieved 2 February 2014. Jobe, AH; Bancalari, E (June 2001). "Bronchopulmonary ... Bronchopulmonary dysplasia is now known to be due to abnormal wound healing in response to injury; it has been linked to ... "The term bronchopulmonary dysplasia was first used by [William] Northway et al. in 1967 to describe a chronic form of injury ...
Bronchopulmonary dysplasia (BPD) is a long-term (chronic) lung condition that affects newborn babies who were either put on a ... Bronchopulmonary dysplasia (BPD) is a long-term (chronic) lung condition that affects newborn babies who were either put on a ... Bronchopulmonary dysplasia (BPD) is a long-term (chronic) lung condition that affects newborn babies who were either put on a ... Bronchopulmonary dysplasia. In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of ...
Babies who are born prematurely or who experience respiratory problems shortly after birth are at risk for bronchopulmonary ... What Is Bronchopulmonary Dysplasia?. Bronchopulmonary dysplasia (BPD), sometimes called chronic lung disease, is a problem with ... How Is Bronchopulmonary Dysplasia Treated?. No medical treatment can cure bronchopulmonary dysplasia right away. Treatment ... What Happens in Bronchopulmonary Dysplasia?. Babies arent born with the condition. It happens when a baby has been on oxygen ...
Bronchopulmonary dysplasia (BPD) or chronic lung disease of prematurity occurs when an infants lungs have not developed ... What is Bronchopulmonary Dysplasia (BPD) / Chronic Lung Disease of Prematurity?. Bronchopulmonary dysplasia (BPD) is a ... What are Signs and Symptoms of Bronchopulmonary Dysplasia?. Signs and symptoms of bronchopulmonary dysplasia include:. * ... How is Bronchopulmonary Dysplasia Treated?. Your care team will use treatments to limit damage to your babys lungs. The goal ...
Bronchopulmonary dysplasia (BPD) is a chronic pulmonary disorder that results from the use of high positive-pressure mechanical ... encoded search term (Bronchopulmonary Dysplasia (BPD) Imaging) and Bronchopulmonary Dysplasia (BPD) Imaging What to Read Next ... Bronchopulmonary Dysplasia (BPD) Imaging Updated: Jan 05, 2021 * Author: Prabhakar Rajiah, MD, MBBS, FRCR; Chief Editor: Eugene ... Bronchopulmonary dysplasia: value of CT in identifying pulmonary sequelae. AJR Am J Roentgenol. 1994 Jul. 163(1):169-72. [QxMD ...
To assess the impact of booster transfusions on oxygen utilization in infants with bronchopulmonary dysplasia, we noninvasively ... Effect of booster blood transfusions on oxygen utilization in infants with bronchopulmonary dysplasia J Pediatr. 1988 Oct;113(4 ... To assess the impact of booster transfusions on oxygen utilization in infants with bronchopulmonary dysplasia, we noninvasively ... before and 24 hours after transfusion therapy in 10 oxygen-dependent infants with bronchopulmonary dysplasia. The infants had ...
span,,b,Background:,/b, Infants with severe bronchopulmonary dysplasia (BPD) are commonly treated with off-label drugs due to ... Background: Infants with severe bronchopulmonary dysplasia (BPD) are commonly treated with off-label drugs due to lack of ... Objective: Our objective was to compare rates of drug exposure between preterm infants with severe bronchopulmonary dysplasia ... Pharmacoepidemiology of Drug Exposure in Intubated and Non-Intubated Preterm Infants With Severe Bronchopulmonary Dysplasia ...
Bronchopulmonary Dysplasia (BPD) - Learn about the causes, symptoms, diagnosis & treatment from the MSD Manuals - Medical ... What is bronchopulmonary dysplasia (BPD)? Bronchopulmonary dysplasia (BPD) is long-term lung damage that happens to some babies ...
Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future ...
Chang YS, Ahn SY, Yoo HS, Sung SI, Choi SJ, Oh WI and Park WS: Mesenchymal stem cells for bronchopulmonary dysplasia: Phase 1 ... Bronchopulmonary dysplasia (BPD) is the most critical complication in preterm neonates and is an independent risk factor ... Berger J and Bhandari V: Animal models of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 307:L936-L947. 2014. ... Jobe AH and Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care. 163:1723-1729. 2001. View Article : Google Scholar ...
Online clinical tool to estimate risk of bronchopulmonary dysplasia in extremely preterm infants ... Online clinical tool to estimate risk of bronchopulmonary dysplasia in extremely preterm infants ... Online clinical tool to estimate risk of bronchopulmonary dysplasia in extremely preterm infants ...
... p16Ink4a in Bronchopulmonary Dysplasia in Children Transpyloric Feeding in Severe Bronchopulmonary Dysplasia Follow-Up Study of ... Stem Cells for Bronchopulmonary Dysplasia Hydrotherapy in Premature Infants With Bronchopulmonary Dysplasia Inhaled Nitric ... Antecedents of Bronchopulmonary Dysplasia Pulmonary Outcomes of Bronchopulmonary Dysplasia in Young Adulthood Aerosolized ... Epidemiological Study for Bronchopulmonary Dysplasia (BPD) in China PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in ...
Palivizumab immunization against respiratory syncytial virus is only cost-effective in infants with bronchopulmonary dysplasia ... verifying an appropriate cost-effectiveness ratio only immunizing children with bronchopulmonary dysplasia in high-risk months. ...
Article Bronchopulmonary Dysplasia Cohort Studies Cytomegalovirus Cytomegalovirus Infections Female Humans Infant Infant, ... "Postnatal Cytomegalovirus Infection and the Risk of Bronchopulmonary Dysplasia" 169, no. 12 (2015). Kelly, Matthew S. et al. " ... 2015). Postnatal Cytomegalovirus Infection and the Risk of Bronchopulmonary Dysplasia. 169(12). Kelly, Matthew S. et al. " ... To investigate the relationship between postnatal CMV infection and bronchopulmonary dysplasia (BPD) and mortality in a large, ...
Pathophysiology and treatment of bronchopulmonary dysplasia. Current issues. Pediatr Clin North Am. 1994 Apr; 41(2):277-315. ...
Bronchopulmonary Dysplasia: New Developments in Treatment and Prevention. / Pierro, Maria. 2019.. Research output: Thesis › ... Pierro M. Bronchopulmonary Dysplasia: New Developments in Treatment and Prevention. 2019. doi: 10.26481/dis.20190917mp ... Pierro, M. (2019). Bronchopulmonary Dysplasia: New Developments in Treatment and Prevention. [Doctoral Thesis, Maastricht ... Pierro, M 2019, Bronchopulmonary Dysplasia: New Developments in Treatment and Prevention, Maastricht University. https://doi. ...
BPD Bronchopulmonary dysplasia (BPD) is a chronic lung disease. It is most often associated with premature birth. Read about ... Bronchopulmonary Dysplasia. Last updated by Dr Colin Tidy Peer reviewed by Dr Krishna Vakharia ... What is bronchopulmonary dysplasia?. BPD is a chronic lung disease that most commonly occurs in premature infants who have ... Bronchopulmonary dysplasia treatment and management[7]. The current therapy for BPD is limited to supportive care including ...
Bronchopulmonary dysplasia. Babies born more than 10 weeks early are at the greatest risk of bronchopulmonary dysplasia. This ... dysplasia. (n.d.).. http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/bronchopulmonary-dysplasia/. ...
Bronchopulmonary Dysplasia (BPD) - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis from the MSD Manuals - ... Diagnosis of Bronchopulmonary Dysplasia *. National Institute of Child Health and Human Development (NICHD) criteria ... Prognosis for Bronchopulmonary Dysplasia Prognosis varies with severity. Most infants gradually transition from mechanical ... National Institute of Child Health and Human Development Criteria for Diagnosis of Bronchopulmonary Dysplasia*. , 32 Weeks ...
Postnatal weight gain in preterm infants with severe bronchopulmonary dysplasia. Girija Natarajan, Yvette R. Johnson, Beverly ... keywords = "bronchopulmonary dysplasia, growth, nutrition, tracheostomy",. author = "Girija Natarajan and Johnson, {Yvette R.} ... Postnatal weight gain in preterm infants with severe bronchopulmonary dysplasia. American journal of perinatology. 2014 Mar;31( ... Postnatal weight gain in preterm infants with severe bronchopulmonary dysplasia. In: American journal of perinatology. 2014 ; ...
ObjectivesAfter participating in this educational activity, attendees should be able to:1. To provide brief overview of lung development.2. To discuss definition of BPD in preterm infants.3. To discuss pathogenesis of BPD.4. To discuss treatment modalities and complications of BPD.FacultyRachana Singh, MDAssociate Professor of PediatricsUMMS - Baystate Faculty DisclosureThe
Keywords : bronchopulmonary dysplasia; lung diseases; infant; respiratory function testing; child. · abstract in Portuguese · ... Impact of bronchopulmonary dysplasia on pulmonary function during childhood: a systematic review. J. Hum. Growth Dev. [online ... INTRODUCTION: Bronchopulmonary dysplasia (BPD) is a multifactorial chronic lung disease that contributes to disruption of ...
Discover the top 25 questions that someone asks himself/herself when is diagnosed with Bronchopulmonary Dysplasia (BPD) , ... Bronchopulmonary Dysplasia (BPD) top 25 questions. Help others answering the top 25 questions of Bronchopulmonary Dysplasia ( ... Living with Bronchopulmonary Dysplasia (BPD). How to live with Bronchopulmonary Dysplasia (BPD)?. 2 answers. ... Bronchopulmonary Dysplasia (BPD) diet. Is there a diet which improves the quality of life of people with Bronchopulmonary ...
... safety study of sildenafil in premature infants with severe bronchopulmonary dysplasia (BPD). ... safety study of sildenafil in premature infants with severe bronchopulmonary dysplasia, ... pilot study to help us get information to design a larger trial of diuretic management for bronchopulmonary dysplasia. ...
Tag: bronchopulmonary dysplasia, diagnostic table by A. Wald, E.N. Akhmadeeva, E.V. YARUKOVA, L.D. PANOVA, P.V. PANOV, ... Tag: bronchopulmonary dysplasia, E. D. BAYKOV, E.N. Akhmadeeva, L.D. PANOVA, P.V. PANOV, perinatal and genetic risk factors, ... Tag › bronchopulmonary dysplasia Immunoprophylaxy of respiratory-syncytial viral infection in prematurely children with ... Tag: 2017, A.I. SAFINA, bronchopulmonary dysplasia, E.V. VOLYANYUK, palivizumab, Practical medicine 10 (17) Pediatrics, ...
Brief Summary of Findings on the Association Between Underlying Bronchopulmonary Dysplasia (BPD) and Severe COVID-19 Outcomes. ...
Objective To analyze the risk factors of bronchopulmonary dysplasia (B... ... bronchopulmonary dysplasia, preterm infants 摘要: 目的 分析合并新生儿呼吸窘迫综合征(NRDS)的胎龄<32周的极低出生体重儿发生支气管肺发育不良(BPD)的危险因素,为临床诊治提供参考依据。方法 选取 ... 3] Jobe AH,Bancalari E. Bronchopulmonary dysplasia[J].Am J Respir Crit Care Med,2001,163(7):1723-1729.. [4] 沙得哈西·卡马力
Bronchopulmonary dysplasia (BPD) is a disease of neonates which occurs as a result of a necessary and very specific postnatal ... Use of Electrical Impedance Tomography for Quantitative Evaluation of Disability Level of Bronchopulmonary Dysplasia. Authors: ... 7] E. Bancalari, N. Claure, "Definitions and diagnostic criteria for bronchopulmonary dysplasia," Semin Perinatol 30, 2006, pp. ... Use of Electrical Impedance Tomography for Quantitative Evaluation of Disability Level of Bronchopulmonary Dysplasia ...
Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: A clinical review. / Simones, Ann A.; ... Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: A clinical review. Pediatric Research. ... Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia : A clinical review. In: Pediatric ... Dive into the research topics of Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: A ...

No FAQ available that match "bronchopulmonary dysplasia"